Clinical and Biochemical Aspects of Gestational Diabetes Mellitus by Brink, H.S. (Huguette)
UITNODIGING
voor het bijwonen 
van de openbare verdediging 
van het proefschrift
Clinical and Biochemical 
Aspects of Gestational 
Diabetes Mellitus
door 
Huguette Stephanie Brink
Woensdag 26 september 2018  
om 13.30 uur 
Prof. Andries Querido zaal
Faculteitsgebouw
Erasmus MC
Dr. Molewaterplein 50
3015 GE Rotterdam
Na afloop bent u 
van harte uitgenodigd
voor de receptie ter plaatse
Paranimfen: 
S.A. Brink 
S.J. van Meurs 
CLINICAL AND BIOCHEMICAL 
ASPECTS OF GESTATIONAL 
DIABETES MELLITUS
Huguette Stephanie Brink
C
LIN
IC
A
L A
N
D
 BIO
C
H
EM
IC
A
L A
SPEC
TS O
F G
ESTATIO
N
A
L D
IA
BETES M
ELLITU
S           H
. S. BRIN
K
UITNODIGING
voor het bijwonen 
van de openbare verdediging 
van het proefschrift
Clinical and Biochemical 
Aspects of Gestational 
Diabetes Mellitus
door 
Huguette Stephanie Brink
Woensdag 26 september 2018  
om 13.30 uur 
Prof. Andries Querido zaal
Faculteitsgebouw
Erasmus MC
Dr. Molewaterplein 50
3015 GE Rotterdam
Na afloop bent u 
van harte uitgenodigd
voor de receptie ter plaatse
Paranimfen: 
S.A. Brink 
S.J. van Meurs 
CLINICAL AND BIOCHEMICAL 
ASPECTS OF GESTATIONAL 
DIABETES MELLITUS
Huguette Stephanie Brink
C
LIN
IC
A
L A
N
D
 BIO
C
H
EM
IC
A
L A
SPEC
TS O
F G
ESTATIO
N
A
L D
IA
BETES M
ELLITU
S           H
. S. BRIN
K
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 1
CLINICAL AND BIOCHEMICAL ASPECTS OF 
GESTATIONAL DIABETES MELLITUS
Huguette Stephanie Brink
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 2
CLINICAL AND BIOCHEMICAL ASPECTS OF GESTATIONAL DIABETES MELLITUS
Thesis, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands 
Printing of this thesis was financially supported by: Maasstad Academie – Maasstad Ziekenhuis, 
ChipSoft B.V. 
ISBN/EAN:   978-94-028-1121-6
Copyright 2018 © Huguette Stephanie Brink 
Design and layout: Legatron Electronic Publishing, Rotterdam, the Netherlands
Printing: Ipskamp Printing, Enschede, the Netherlands
All rights reserved. No parts of this thesis may be reproduced, distributed, stored in a retrieval 
system, or transmitted in any form or by any means without prior permission of the author, or when 
appropriate, the publishers of the publications.
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 3
CLINICAL AND BIOCHEMICAL ASPECTS OF 
GESTATIONAL DIABETES MELLITUS
P R O E F S C H R I F T
ter verkrijging van de graad doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. R.C.M.E. Engels  
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
Woensdag 26 september 2018 om 13.30 uur 
door
Huguette Stephanie Brink
Geboren te Hilversum
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 4
PROMOTIECOMMISSIE 
Promotor  Prof.dr. A.J. van der Lelij
Copromotor  Dr. J. van der Linden 
Overige leden Prof.dr. P.J.E. Bindels
 Prof.dr. R.P.M. Steegers-Theunissen 
 Prof.dr. G.H.A. Visser 
Paranifmen 
S.A. Brink
S.J. van Meurs 
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 5
C O N T E N T S
Chapter 1 Introduction  7
Part I Biomarkers and Prediction
Chapter 2  The Potential Role of Biomarkers in Predicting Gestational Diabetes Mellitus 21
Endocr Connect. 2016 Sep;5(5):R26-34
Chapter 3  The Ghrelin System and Gestational Diabetes Mellitus 35
Diabetes Metab. 2017 Nov 8. pii: S1262-3636(17)30554-2.
Part II Evaluating Current Management 
Chapter 4  Maternal and Neonatal Outcomes of Gestational Diabetes Mellitus 45
Submitted for publication
Chapter 5 Comparison of SMBG and CGM in Gestational Diabetes Mellitus  59
Submitted for publication
Chapter 6  Metformin in Women at High Risk of Gestational Diabetes Mellitus 71
 Diabetes Metab. 2018 Jun;44(3):300-302. 
Part III Postpartum and Beyond
Chapter 7  Investigating Screening for Diabetes in Women With a History of 87
Gestational Diabetes Mellitus 
Neth J Med. 2016 Dec;74(10):429-433.
Chapter 8 Discussion 99
Part IV Summary and Appendices 
Chapter 9 Summary 117
Chapter 10 Samenvatting 123
Chapter 11 Portfolio 129
About the author  131
Dankwoord 133
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 6
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 7
C H A P T E R  1 
I N T R O D U C T I O N 
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 8
8 | Chapter 1
GESTATIONAL DIABETES MELLITUS
Gestational diabetes mellitus (GDM) is defined as any glucose intolerance with onset or first 
recognition during pregnancy. Recently, the definition has been updated to diabetes diagnosed 
in the second or third trimester of pregnancy that is not clearly overt diabetes. Type 1 or 2 diabetes 
mellitus (T1DM or T2DM) diagnosed before pregnancy, are referred to as pregestational diabetes 
and convey higher maternal and neonatal risk (1). 
Epidemiology
GDM is the most common metabolic disorder during pregnancy with an estimated prevalence 
of 1–14%, depending on the population studied and the diagnostic criteria used. GDM accounts 
for the vast majority of pregnancies affected by diabetes mellitus (1). The prevalence is increasing 
worldwide in line with the obesity and T2DM epidemic, with major implications for public health (2). 
Risk factors for GDM include: advanced maternal age, body mass index (BMI) > 30 kg/m², previous 
pregnancy with GDM, previous child with birth weight > 4500 gram or > 95th percentile, history of 
polycystic ovary syndrome, history of unexplained intra-uterine death, and family history of diabetes 
mellitus and certain ethnic risk groups (e.g. Asian, Caribbean) (2,3). 
(Patho)physiology
In pregnancy, insulin secretion increases in the first trimester whereas insulin sensitivity remains 
unchanged. From the second trimester onwards, insulin sensitivity progressively decreases to levels 
that approximate insulin resistance seen in type 2 diabetes mellitus (T2DM). Placental hormones 
such as progesterone, oestradiol, cortisol, prolactin and human placental lactogen, released mid-
pregnancy contribute to the insulin resistant state (4). The development of insulin resistance serves 
as a physiological adaptation of the mother to ensure adequate nutrient supply for the rapidly 
growing foetus (5). 
To compensate, a 2- to 2·5-fold increase in insulin secretion is necessary to maintain glucose 
levels within the normal range (5). GDM develops when pancreatic β-cells are unable to increase 
insulin secretion to levels that are sufficient enough to counteract the corresponding fall in insulin 
sensitivity. 
Obesity, inflammation and GDM
Obesity is one of the greatest public health problems of the 21st century (6). Obese pregnant 
women are three times as likely to develop GDM as non-obese individuals (7). Pregravid obesity 
and excessive gestational weight gain (GWG) are often observed in women with GDM. Both are 
independent predictors of adverse pregnancy outcome (8). GDM and obesity combined have an 
even greater effect on pregnancy complications. 
Adipose tissue does not only function as an energy storage entity but also as a biologically active 
endocrine organ, secreting adipokines (i.e. adiponectin, leptin) and inflammatory markers (i.e. tumor 
necrosis factor- alpha (TNF-α), interleukin-6 (IL-6)). Obesity is characterized by an altered production 
of inflammatory markers and adipokines causing a state of chronic low-grade inflammation (9). 
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Obesity and inflammation are increasingly being recognized as pathophysiological features of GDM 
(10). As a result, there is an increased interest in adipokines and other biomarkers in understanding 
the pathophysiology of GDM. The detection of biomarkers before the onset of hyperglycaemia may 
aid in the identification of women at risk. 
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Figure 1 | Proposed model of relation between obesity, inflammation and GDM
Extracted with permission from Abell SK. Inflammatory and Other Biomarkers: Role in Pathophysiology and Prediction of 
Gestational Diabetes Mellitus Int J Mol Sci. 2015 Jun; 16(6): 13442–134
Ghrelin 
Ghrelin is a gastro-intestinal peptide hormone and the endogenous ligand for the growth hormone 
secretagogue receptor (GHSR)1a. Total serum ghrelin levels are composed of acylated ghrelin 
(AG) and unacylated ghrelin (UAG). Ghrelin has a wide-range of biological activities and has been 
implicated in the regulation of glucose homeostasis (11). Furthermore, ghrelin or ghrelin mRNA is 
expressed in human ovary, testis and placenta, suggesting a role in fertility and pregnancy (12). It has 
been reported that ghrelin levels are lower in women with GDM, which may reflect the inhibitory 
effect of insulin on ghrelin secretion (13). Other studies found decreased ghrelin levels in pregnancy 
irrespective of glucose tolerance (14). However, to date, most studies measured total ghrelin, without 
differentiating between AG and UAG (15). The value of ghrelin as a biomarker in GDM needs to be 
evaluated with a double-antibody technique. 
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MATERNAL AND NEONATAL OUTCOMES 
Pregnancies complicated by GDM are associated with an increased risk of adverse maternal 
and neonatal outcomes. These risks are related to uncontrolled hyperglycaemia. Data from the 
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) Trial established a linear relationship 
between maternal glucose levels and pregnancy complications (16). 
Women with GDM are at increased risk of pregnancy-induced hypertension, preeclampsia and 
caesarean section. Moreover, women have a ~30% risk of GDM recurring in a subsequent pregnancy 
with higher rates observed in non-white populations (17,18). After pregnancy, hyperglycaemia 
resolves in most cases. However, women have an increased risk of T2DM and cardiovascular disease 
later in life (19). Evidence has shown that the risk of T2DM might be as high as 50% in the 5–10 years 
postpartum (20).
Maternal hyperglycaemia leads to increased transfer of glucose, lipids, and amino acids via the 
placenta. Maternal insulin cannot cross the placenta which results in foetal hyperinsulinaemia 
(21). This leads to fat accumulation, with insulin acting as a growth factor, stimulating intrauterine 
growth (22,23). Thus, foetal hyperinsulinaemia results in excessive growth of the foetus, leading to 
macrosomia (birth weight greater than 4000 g) or large-for-gestational-age (LGA) defined as birth 
weight > 90th percentile. This in turn is related to a higher frequency of birth trauma including 
shoulder dystocia, nerve palsies and clavicle fractures (16). Other neonatal complications include 
premature birth, neonatal hypoglycaemia, neonatal hyperbilirubinaemia (jaundice) and respiratory 
distress syndrome (24). Long-term risks in offspring include an increased risk of obesity and T2DM 
(25-27). 
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Figure 2 | Short and long-term outcomes of GDM 
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SCREENING METHODS AND DIAGNOSTIC CRITERIA 
Screening for GDM is generally performed in women with risk factors or in case of symptoms (e.g. 
polyhydramnios or suspected foetal macrosomia) by means of an oral glucose tolerance test (OGTT). 
This test requires women to ingest a glucose solution containing 75-g of glucose after an overnight 
fast. Before and after administration of the glucose containing solution, plasma glucose values are 
measured. The approach to screening for GDM varies among leading international organisations 
and even within countries. Some expert groups recommend screening based on the presence of 
risk factors, while others state that this method fails to adequately detect all women with GDM and 
advocate universal screening (7,28,29?). Controversy regarding screening also exists due to lack of 
universally accepted diagnostic criteria and uncertainty about the threshold at which treatment 
becomes beneficial. O’Sullivan established the first diagnostic criteria in the 1960’s and modified 
versions are still used to date. However, these criteria were designed to identify those at risk of T2DM 
after pregnancy and not those who are at risk of adverse pregnancy outcomes (30). 
In 2010, the Internal Association of Diabetes and Pregnancy Study Groups (IADPSG) established new 
diagnostic criteria based on data from the HAPO trial (16,31). The IADPSG criteria are based upon 
an OR of 1.75 for negative pregnancy outcomes (75 g OGTT 0 h ≥ 5.1 mmol/l, 1 h ≥ 10.0 mmol/l, 
2 h ≥ 8.5 mmol/l) and endorsed by global health organisations but not by the Dutch Society of 
Obstetrics and Gynaecology (3). 
In the Netherlands, the national guideline “Diabetes and Pregnancy” recommends screening in 
women with one or more of the following risk factors: a first degree relative with diabetes mellitus; 
pre-gestational body mass index > 30 kg/m²; previous child with birth weight > 4500 gram or > 95th 
percentile; history of unexplained intra-uterine foetal death, history of polycystic ovary syndrome 
and certain high-risk ethnicities (i.e. Afro-Caribbean, Hindu). Screening is performed by means of 
a 75-g OGTT between 24 and 28 weeks of gestation. Women with a history of GDM are screened 
between 16 and 18 weeks and 24 and 28 weeks of gestation. GDM is diagnosed if at least one value 
of plasma glucose level is equal to or exceeds the threshold (fasting glucose: ≥ 7.0 mmol/L and/or 
2-hours post glucose load ≥ 7.8 mmol/L) (3). These diagnostic cut-off criteria are based on the World 
Health Organisation’s (WHO) 1999 criteria (32). 
MANAGEMENT OF GDM 
Treatment 
The treatment of GDM has been widely reviewed and proven to be effective in the reduction of 
adverse pregnancy outcome (33-35). Dietary and lifestyle intervention is the cornerstone of GDM 
treatment. For the majority of patients, optimal nutrition and a healthy lifestyle are sufficient to 
achieve glycaemic control. Treatment targets for GDM are: fasting glucose ≤ 5.3 mmol/L; 1-hour 
postprandial ≤ 7.8 mol/L; and/or 2-hours postprandial ≤ 6.7 mmol/L, capillary). If glycaemic targets 
are not met, then additional insulin therapy is the next form of treatment (3). The use of oral anti-
diabetic agents in the treatment of GDM is gaining ground with data showing efficacy and safety 
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(36,37). However, long-term follow-up in children exposed to oral agents in pregnancy is required for 
widespread clinical acceptance (38,39). 
Data on pregnancy outcomes under the current national screening and treatment guideline is scarce. 
Koning et al. showed that the number of adverse pregnancy outcomes in GDM was comparable 
with the general obstetric population in the northern region of the Netherlands (40). However, the 
incidence of LGA infants remained significantly increased. Most women in their GDM cohort were 
Caucasian women and is therefore not a reflection of all regions of the Netherlands. 
Metformin 
Metformin is a biguanide analogue, increasing insulin sensitivity and decreasing hepatic glucose 
production (41). Metformin is an emerging contender in the treatment of GDM (42). It is associated 
with less gestational weight gain and a lower risk of hypoglycaemia (43,44). Theoretically, metformin 
might reduce insulin resistance in pregnancy, causing a reduction in maternal glucose levels and 
subsequent foetal hyperinsulinaemia. In turn it could have a positive effect on the incidence of GDM 
and related pregnancy outcomes. To date, two large double-blind randomized-controlled trials 
(the EMPOWar trial and the MOP trial) showed no significant effect of metformin on birth weight 
percentile in obese pregnant women (45,46). However, other high-risk populations are yet to be 
investigated. 
Monitoring
Treatment of GDM aims to maintain glucose levels equal to those of pregnant women without 
GDM. Therefore, insight into glucose regulation during the treatment of GDM is vital. Monitoring of 
treatment is currently based on self-monitoring of blood glucose (SMBG) by means of finger-stick 
glucose measurements. SMBG can reduce foetal overgrowth but the optimal frequency is unknown 
and compliance is low (47,48). Data has shown that 22% percent of women with GDM falsify or invent 
glucose values (49). Furthermore, SMBG does not provide a longitudinal glucose profile and could 
well hide periods of hyper-and hypoglycaemia. Blinded continuous glucose monitoring (CGM) 
is a monitoring technique which provides insight into the frequency and duration of hypo-and 
hyperglycaemic events (50). In patients with diabetes mellitus, CGM has shown the potential to aid 
clinical decision making in selected patient groups (51). 
POSTPARTUM AND BEYOND 
As previously mentioned, GDM is a risk factor for the development of T2DM and cardiovascular disease 
after pregnancy (52). With the increasing number of women with obesity and GDM, prevention of 
T2DM after pregnancy has become important. Lifestyle intervention and pharmacotherapy have 
both shown to reduce the incidence of T2DM in women with a history of GDM (53). Therefore, 
adequate diabetes screening programs are essential in this population. Postpartum screening 
attendance rates are low and little is known about long-term screening rates. In the Netherlands, 
diabetes screening is recommended annually in the first five years after pregnancy and every three 
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years thereafter (54). Data on adherence to these recommendations and the incidence of T2DM is 
limited. 
SCOPE AND AIMS OF THIS THESIS 
This thesis seeks to explore the overall management of GDM. The first aim is to investigate biomarkers 
and risk stratification. Which potential biomarkers can be used in the prediction of GDM? Is Ghrelin a 
useful biomarker? The second aim is to evaluate current management of GDM. Is the current national 
screening and treatment guideline for GDM effective in reducing GDM related complications? What 
is the role of blinded continuous glucose monitoring in treatment monitoring? The third aim is to 
study the adherence to long-term diabetes screening recommendations in women with GDM. 
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Introduction
Gestational diabetes mellitus (GDM) is defined as any glucose intolerance with onset or first 
recognition during pregnancy. GDM has a prevalence of ~7% worldwide, depending on the 
population studied and diagnostic criteria used (1). The incidence of GDM is increasing in line with 
the global rise of obesity and type 2 diabetes mellitus (T2DM) (2). GDM occurs when pancreatic β-cells 
cannot compensate for the increased levels of insulin resistance which occurs during pregnancy (3). 
Insulin resistance and β-cell dysfunction are two known mechanisms, however the exact cellular 
mechanisms remain to be elucidated (4). GDM is associated with maternal and neonatal short- and 
long-term complications (5,6). For the offspring this includes a predisposition for development 
of obesity and T2DM (7,8). Long-term maternal risks include T2DM and cardiovascular disease (9). 
Currently, GDM is diagnosed in the late second trimester, possibly exposing the infant to intra-
uterine metabolic alterations and epigenetic programming for a significant period of time. Reported 
evidence suggests that metabolic alterations can predispose infants to long-term pathology (10,11). 
Detection and management of GDM in pregnancy can reduce the frequency of adverse pregnancy 
outcomes (12,13). Hence, there is need for improved prediction as current risk stratification fails to 
correctly identify all women with GDM (14,15). 
Investigating the role of adipokines associated with the pathophysiology of GDM has gained interest 
(16,17). Adipokines have in recent years been posed as the link between adiposity and adverse 
complications such as insulin resistance. Identification of early biomarkers in pregnant women, 
who subsequently develop GDM, may result in improved understanding of GDM pathogenesis. 
Combining biomarkers and risk factors into a predictive model may add to early prediction of GDM, 
evoke effective prevention strategies and may ultimately reduce complications associated with 
GDM. 
The aim of this review is to 1) identify potential predictive biomarkers in GDM and 2) discuss the role 
of incorporating predictive biomarkers into clinical risk prediction models, for the stratification of 
high-risk patients. 
Epigenetic footprint 
Metabolic alterations such as impaired glycaemic control during foetal development can lead 
to functional and structural alterations in the foetus, resulting in a predisposition for developing 
chronic metabolic diseases later in life. These alterations are also referred to as ‘foetal programming’ 
and they can cause epigenetic changes (10). 
Epigenetic changes ascribe to the change in the biochemical structure of DNA that ultimately 
alters gene expression. This includes DNA methylation, histone modification and non-coding RNA 
processes (18). Epigenetic changes have been observed in many disease states and offer biochemical 
evidence of the detrimental effects of adverse developmental conditions and subsequent disease 
(10). This relationship has been supported by epidemiologic and animal studies (19-22). Furthermore, 
it has been reported that maternal insulin resistance also causes insulin resistance in the foetus, as 
early as the embryonic stage (23). Multiple studies have linked maternal GDM with the development 
of obesity and T2DM in children (11,24), who are eight-times more likely to develop T2DM than non-
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GDM children (25). Therefore, there is a strong need for early detection of GDM. Detection preceding 
the hyperglycaemia might avoid subsequent harm. Investigating early predictive biomarkers in 
GDM may be a step in this direction. 
Obesity, inflammation and GDM
More women of childbearing age are entering pregnancy being overweight or obese (26). Obese 
pregnant women have a three-fold risk for developing GDM (27). The global increase in GDM is largely 
attributed to the ongoing obesity pandemic (28). Obesity is characterized by altered production of 
proinflammatory cytokines by adipocytes causing a state of chronic low-grade inflammation (29), 
driving the expression and production of proinflammatory (tumor necrosis factor- alpha (TNF-α), 
interleukin-6 (IL-6)) and anti-inflammatory cytokines or adipokines (adiponectin, leptin, visfatin) (30). 
Adipokines have a clear regulatory role in metabolism, including modifying insulin secretion and 
sensitivity, appetite, energy control and inflammation (31). Clinical and epidemiologic studies have 
described a sound relation between obesity, chronic low-grade inflammation and the development 
of T2DM (32). In normal pregnancy, the immune system is subjected to changes with a delicate 
balance between production of pro- and anti-inflammatory cytokines. Pregnancies in obese 
individuals further enhance the proinflammatory profile leading to an imbalance and, therefore, 
possible complications. It is increasingly being recognized that inflammation is a pathophysiologic 
feature of GDM (33,34). In GDM, a pro-inflammatory state prevails and the increased production of 
proinflammatory cytokines debilitates insulin signalling (35). Down regulation of adiponectin and 
anti-inflammatory markers such as IL-4, IL-10 and upregulation of pro-inflammatory cytokines such 
as IL-6 and TNF- α can be observed in GDM (35,36). 
Adipokines 
Adiponectin 
Adiponectin is an adipocyte-derived protein. It contains anti-atherogenic, anti-inflammatory and 
insulin-sentizing properties (37). Adiponectin is inversely correlated with obesity, hypertension, 
serum lipids and coronary artery disease (37,38). Decreased adiponectin levels have also been 
associated with an increased risk of T2DM (39,40). Adiponectin levels are known to decrease 
progressively during normal pregnancy, probably in response to decreased insulin sensitivity (41). 
Several studies have also shown reduced adiponectin levels during mid-pregnancy (24–28 weeks) 
in GDM compared to controls (42-47), relating low levels of adiponectin to the onset of insulin 
resistance and diminished β-cell function (48). A systematic review and meta-analysis of adiponectin 
concentrations in 560 GDM and 781 controls underlined a significantly decreased adiponectin level 
in women with GDM versus controls (47). However, it must be noted that results are in light of a 
significant heterogeneity among the included studies. In recent years, prospective studies have 
addressed the role of adiponectin as a possible early predictor of GDM. Lower levels of adiponectin 
in the first trimester of pregnancy are associated with a greater risk for developing GDM (49-51), 
suggesting that a down-regulation of adiponectin may be a predictor of GDM. However, in a 
systematic review and meta-analysis, adiponectin had a moderate effect for predicting future GDM 
with pooled diagnostic odds ratio (DOR) of 6.4 (95% CI 4.1, 9.9), a summary sensitivity of 64.7% 
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(95% CI 51.0%, 76.4%) and a specificity of 77.8% (95% CI 66.4%, 86.1%) (52). Furthermore, a nested-
case control study showed that low pre-pregnancy adiponectin levels are associated with a 5.0-
fold increased risk of developing GDM (53). This association remained significant after adjusting for 
known risk factors for GDM. This might be relevant for clinical practice as it identifies a group of high-
risk women that might otherwise not have been identified. Adiponectin therapy has been tested in 
animal models of obesity and it has been shown to improve glycaemia and reduce hyperinsulinemia 
without alterations in body weight (54). 
In summary, lower levels of adiponectin are linked to obesity, type 2 diabetes and GDM. Adiponectin 
might play a role in the pathophysiology of GDM and can be seen as a promising predictive 
biomarker for GDM. Further research addressing lifestyle interventions or adiponectin intervention 
therapy is needed to further establish the role adiponectin in GDM. 
Leptin 
Leptin is an adipocyte-derived hormone. It is predominantly produced by adipocytes but is also 
produced in ovaries and the placenta. It regulates energy balance through hypothalamic pathways 
(55). Increased leptin concentrations are associated with weight gain, obesity and hyperinsulinaemia 
(56). Maternal leptin levels are known to increase 2–3 fold in pregnancy, likely due to placental 
secretion (57). Increased leptin levels have been reported in women with GD (47). Inflammatory 
markers, such as IL-6 and TNF-α probably also play a role in the pathophysiology of GDM by 
promoting chronic low-grade inflammation, while further increasing leptin concentrations (58). A 
prospective cohort study reported increased concentrations of leptin before 16 weeks gestation, 
independent of adiposity, which were associated with an increased risk of GDM (59). Another small 
study showed that leptin was increased in all women during pregnancy, with highest concentrations 
observed in obese GDM subjects. Adjusted for fat mass, this correlation disappeared, however (35). 
Generally speaking, current evidence is limited, in part due to confounding effects of measures of 
adiposity. Leptin is likely to be involved in the pathophysiology of GDM but appears to be a poor 
predictor of GDM. 
Visfatin 
Visfatin is an adipokine and is mostly produced by visceral fat. It has endocrine, paracrine and 
autocrine actions (60). Increased visfatin levels have been reported in obesity, metabolic syndrome 
and T2DM (61,62). In pregnancy, visfatin levels progressively increase up to the second trimester, 
after which they decease again with the lowest concentrations observed in the third trimester (63). 
In GDM, reports on visfatin levels have thus far been inconsistent, as both decreased and increased 
levels have been reported (64-66). Another study showed that visfatin measured in the first trimester 
was better in the prediction of GDM compared to CRP, Il-6, adiponectin and leptin (67). In a case-
control study, visfatin levels measured in the first trimester were increased in the GDM group but 
when added to other maternal risk factors, the detection rate for GDM did not improve (68). Results 
thus far suggest that visfatin is a potential biomarker in GDM, but additional prospective studies are 
definitely needed to further investigate the relationship between visfatin and GDM. 
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Resistin 
Resistin is an adipose-derived hormone expressed by monocytes, macrophages and adipocytes 
(69). Resistin is positively associated with adiposity. Resistin levels are known to increase during 
pregnancy, probably due to weight gain (58,70). A potential link between resistin, adiposity and 
insulin resistance in pregnancy might exist but to date remains inconclusive due to conflicting 
reports from case-control studies (71,72). Nested-case control studies, investigating resistin levels 
in early pregnancy, found no differences in resistin levels between GDM and controls (adjusted for 
BMI) (36,51). A prospective study with larger sample size than the previous case-control studies also 
showed no significant association between resistin and GDM (73). Other studies have shown elevated 
maternal levels of resistin in GDM (70,71,74). A systematic review showed no significant association 
between resistin levels and GDM pregnancies (75). Significant heterogeneity among studies was 
a major issue in the analysis. Currently there is no sound evidence that resistin is involved in the 
pathophysiology or prediction of GDM. 
Other inflammatory mediators 
Tumor necrosis factor-alpha (TNF-α)
TNF-α is a pro-inflammatory cytokine and is produced by monocytes and macrophages. It affects 
insulin sensitivity and secretion through impairing β-cell function and insulin signalling pathways, 
resulting in insulin resistance and possibly GDM (76). Multiple studies have reported increased 
maternal TNF-α levels in subjects with GDM, predominantly in late pregnancy (77-79). A meta-
analysis also showed increased TNF-α levels in GDM versus controls. Subgroup analysis revealed that 
this relation remained significant when compared to BMI-matched controls (47). The increased levels 
are thought to be due to increased oxidative stress and inflammation associated with the impaired 
glucose metabolism (80). A small nested-case control study with only 14 cases and 14 controls 
addressing the predictive value of TNF-α showed no differences between women with GDM and 
controls (36). In a prospective study in GDM and controls, TNF-α levels were measured pre-gravid, 
at 12–14 weeks and 34–36 weeks. TNF-α levels were increased at 34–36 weeks of gestation and 
were inversely correlated with insulin sensitivity (35). Further prospective studies are required to 
investigate the predictive value of TNF-α in GDM, adjusting for measures of adiposity. 
High sensitivity C- reactive protein (hsCRP)
(hs)CRP is an acute-phase protein and produced in response to tissue injury, inflammation and 
infection. (hs)CRP has been shown to be associated with i.e. obesity and diabetes mellitus. In turn, it 
is well known that obesity is associated with inflammation, which contributes to insulin resistance. 
Elevated first trimester (hs)CRP levels are associated with GDM risk (P for trend=0.007). After 
adjusting for pre-pregnancy BMI, family history of DM and nulliparity, women with (hs)CRP in the 
highest quartile had a 3.5-fold increased risk of GDM as compared to those in the lowest quartile (34). 
Wolf et al. also reported that first-trimester CRP levels were significantly increased among women 
who subsequently developed GDM compared with control subjects (3.1 vs. 2.1 mg/L, P < 0.01). 
After adjusting for age, race/ethnicity, smoking, parity, blood pressure, and gestational age at CRP 
sampling, the increased risk of developing GDM among women in the highest compared with the 
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lowest tertile was 3.6 times higher (95% CI 1.2–11.4). When adjusted for BMI this association was 
not found anymore, however (81). Berggren et al. evaluated whether first-trimester (hs)CRP was 
predictive for third-trimester impaired glucose tolerance (IGT). (hs)CRP was positively associated 
with IGT but, again, the association disappeared when adjusted for BMI (82). Thus far, the positive 
association of (hs)CRP and GDM seems to be in part mediated by BMI. 
Sex-hormone binding globuline (SHBG) 
SHBG is a glycoprotein and plays a role in the regulation and transport of sex hormones. In vitro, 
SHBG has been proposed as a marker in insulin resistance as it has shown that insulin and insulin-like 
growth factor cause inhibition of SHBG secretion (83). Indeed, a relation between low levels of SHBG 
and T2DM has been reported (84). A prospective cross-sectional study evaluating the SHBG serum 
levels reported that SHBG concentrations were significantly lower in GDM subjects than in normal 
pregnancies (85). Furthermore, in women who were treated with insulin, SHBG levels were reported 
to be even lower (86). This might suggest that SHBG could help to differentiate or predict the women 
who will require insulin therapy. The overall additional clinical and predictive value of these results 
is limited as testing on GDM is already routinely performed at this stage of pregnancy. A prospective 
observational study (n=269) evaluating several biomarkers earlier than 15 weeks of gestation 
showed that low levels of SHBG were associated with an increased risk of GDM. This association 
was independent of other risk factors (BMI, smoking, blood pressure). Using the cut-off value of 
211.5 mmol/L, SHBG showed an acceptable sensitivity of 85% but a low specificity of 37%. Adding 
(hs)CRP increases the specificity to 75.46%, however (87). Another prospective cross-sectional study, 
addressing the predictive value of SHBG for the diagnosis of GDM, reported that low levels of SHBG 
assessed between 13–16 weeks of gestation were positively associated with the development of 
GDM (n=30) (P < 0.01) (88). A limitation in this study, however, was that they could not establish an 
SHBG cut-off value for a constant term of pregnancy. A nested-case control study showed that non-
fasting SHBG in the first trimester was consistently associated with an increased risk for GDM (17). 
Other potential biomarkers 
Adipocyte fatty acid-binding protein (AFABP) is an independent risk predictor for metabolic syn-
drome, T2DM and cardiovascular disease (89). Two studies have reported increased concentrations 
in GDM (90,91). Studies investigating the predictive value of AFABP in GDM have not been performed 
to date, however. IL-6 is a proinflammatory cytokine and is increased in obesity and associated with 
indices of adiposity and insulin resistance, such as body mass index (BMI) (92,93). Controversy exists 
regarding the changes in circulating levels of IL-6 in obesity. The relationship between IL-6 and 
insulin action appears to be mediated via adiposity (94). However, in a case-control study, plasma 
IL-6 levels have shown to be elevated when adjusted for BMI in women with GDM (95). Low levels 
of vitamin D have been associated in obesity and T2DM. In pregnancy, low levels are also often 
observed (96). Low vitamin D levels in the first trimester were also associated with a higher risk for 
GDM (adjusted for confounders and risk factors) (96). Recent meta-analyses have supported this 
finding, but the included studies were not all randomized controlled (97). Future RCTs are needed to 
further clarify the predictive role of vitamin D. 
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Clinical prediction models incorporating biomarkers 
Current screening methods only identify women who already have impaired glucose metabolism. 
Ideally, subjects with high risk of GDM should be identified before they exceed the oral glucose 
tolerance test (OGTT) threshold values. Early prediction would allow for timely intervention that 
could limit gestational weight gain and obesity and possibly the onset of GDM. Current screening 
methods have moderate detection rates (98,99). Clinical risk prediction models have been 
investigated in GDM. For example, the development of GDM can be predicted from the ethnicity, 
family history, history of GDM and body mass index. The model showed an area under the receiver 
operating characteristic curve of 0.77 (95% CI 0.69–0.85) (100). If an OGTT was performed in all 
women with a predicted probability of 2% or more, 43% of all women would be tested and 75% 
of the women with GDM would be identified (100). Furthermore, in a large prospective cohort 
(n=7929), the best performing model, based on ethnicity, BMI, family history of diabetes and past 
history of GDM showed a sensitivity, specificity and AUC of 73% (66–79), 81% (80–82) and 0.824 
(0.793–0.855), respectively, for the identification of GDM cases requiring insulin therapy (101). 
Introducing biomarkers to a set of clinical risk factors may enhance predication rates. For example, 
tissue plasminogen activator (t-PA) and low HDL cholesterol were independent significant predictors 
of GDM. The addition of these biomarkers to a set of demographic and clinical risk factors increased 
the area under the curve (ROC) from (0.824 to 0.861) (102). t-PA in the prediction of GDM is a novel 
finding but previous work has shown that t-PA is associated with an increased risk of T2DM (103). 
Another study demonstrated that elevated plasma insulin and reduced adiponectin levels in the 
first trimester improved GDM identification rates compared to clinical factors alone (36). Maternal 
risk factors alone showed a prediction rate of 61% for GD, adding adiponectin and SHBG increased 
detection rates to 74% (16). Investigators in another study showed that adding adiponectin to a set 
of clinical risk factors increased the area under the receiver-operating curve increased significantly 
(104). Adding maternal visfatin and adiponectin to a set of maternal risk factors showed a detection 
rate of 68% (95% CI 58.3–76.3%) (68). The clinical implementation of such multi-parametric prediction 
models depends on significant reduction in adverse pregnancy outcomes, practical acceptability 
and cost-effectiveness. Ultimately, these models require prospective validation studies and further 
identification of predictive threshold values for these biomarkers. 
Conclusion
GDM is currently detected in late pregnancy, unnecessarily exposing the infant to harmful 
intrauterine conditions. There is a definite clinical need to better predict and detect GDM early 
in pregnancy in order to prevent further harm to mother and child. Adiponectin is probably one 
of the most promising candidates in the prediction of GDM. The clinical value of implementing 
a combined clinical model is questionable as the current level of evidence is weak due to study 
design, differences in diagnostic criteria and assay methods used. Well-designed prospective studies 
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addressing current limitations are needed to identify reliable predictive biomarkers in GDM and 
their additional value to current clinical prediction tools. 
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INTRODUCTION
Gestational diabetes mellitus (GDM) is associated with an adverse pregnancy and perinatal outcome. 
A variety of serum biomarkers (e.g. inflammatory cytokines, adipokines and other circulating proteins) 
have been explored in attempts to identify a reliable predictor in early pregnancy for subsequent 
development of GDM, but so far none have been found (1). Hence, the pool of biochemical markers 
should be explored further. 
Ghrelin is a gastro-intestinal peptide hormone and the endogenous ligand for the growth hormone 
secretagogue receptor (GHSR)1a. Total serum ghrelin levels are composed of acylated ghrelin 
(AG) and unacylated ghrelin (UAG). The enzyme ghrelin O-acyltransferase (GOAT) is required for 
the acylation of ghrelin. Ghrelin seems to have a wide-range of biological activities and has been 
implicated in the regulation of glucose homeostasis (2). 
Ghrelin or ghrelin mRNA is expressed in human ovary, testis and placenta, suggesting a role in fertility 
and pregnancy (3). The pathophysiological role of ghrelin in GDM remains unclear, however. It has 
been reported that ghrelin levels are lower in women with GDM, which may reflect the inhibitory 
effect of insulin on ghrelin secretion (4). Other studies found decreased ghrelin levels in pregnancy 
irrespective of glucose tolerance (5). However, to date, most studies measured total ghrelin, without 
differentiating between AG and UAG. Furthermore, single-antibody ghrelin assays recognize the 
COOH-terminal (total ghrelin) or the acylated NH2-terminal part of the peptide (AG) and therefore 
measure full-length ghrelin as well as circulating fragments of ghrelin with unknown biological 
activity. It has been estimated that 60% of the ghrelin measured using these assays is fragmented 
(6). We used a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) assay that 
measures full-length AG and UAG. We hypothesized that women with GDM have a higher degree of 
insulin resistance and hyperinsulinemia, with subsequently lower ghrelin levels than women with 
normal glucose tolerance (NGT). The aim of this study was to compare AG, UAG levels and AG/UAG 
ratios between pregnant women with GDM and NGT. 
METHODS & MATERIALS
Subjects
In the study 19 pregnant women with GDM and 19 women with NGT were enrolled. Women 
were prospectively recruited from the gynaecology outpatient clinic of the Maasstad Hospital, 
Rotterdam, the Netherlands. Women with a singleton pregnancy, ≥ 18 years old, gestational age 
between 24–28 weeks, and a high risk of GDM according to the Dutch Society of Obstetrics and 
Gynaecology (7), were eligible for inclusion. Women were excluded if they met the following criteria: 
endocrine disorders such as acromegaly, pre-existing type 2 diabetes mellitus, Cushing’s syndrome 
or the use of glucocorticoid medication, inflammatory diseases or active infections, and history of 
gastrointestinal surgery or hormonal treatment before or during pregnancy, including insulin. All 
subjects were screened for GDM between 24–28 weeks of gestation by means of a 75-g oral glucose 
tolerance test (OGTT) and the diagnosis of GDM was based on the IADPSG diagnostic criteria (8). 
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Blood samples were drawn during fasting and 2-hours post glucose load. Patient demographics 
such as age, BMI (kg/m²), first trimester glucose (mmol/L) and gestational age at sampling (weeks) 
were obtained from electronic medical records. All patients gave written informed consent before 
inclusion in this study. This study was approved by the medical ethics committee. 
Materials 
Vacutainers from Becton Dickinson (Breda, Netherlands; cat# 367899; 6 mL K2 EDTA) were used. 
4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Pefabloc, SC AEBSF) was purchased from 
Roche Applied. Science (cat# 11429876001; Almere, Netherlands). Aliquots of 200 mg/mL stock 
solutions of AEBSF were prepared in distilled water and stored at -80°C for a maximum of 3 months. 
Human AG and UAG are determined by a double-antibody sandwich technique. The enzyme 
immunoassay (EIA) kits were obtained from Bertin Pharma (Montigny-le-Bretonneux, France; 
A05106 and A05119, respectively).
OGTT, sample collection and storage 
After an overnight fast, the 75-g OGTT was performed. Baseline serum parameters were glucose 
(4ml heparin tube), HbA1c (8.5ml serum separating tube), AG and UAG (4ml EDTA). Two hours after 
glucose ingestion we assessed: glucose (4ml heparin tube) and AG and UAG (4mL EDTA). Immediately 
after sample collection, AEBSF (dilution 1:100) was added to the AG and UAG blood samples to 
prevent des-acylation of AG. Tubes were carefully mixed by inversion and stored on water ice (0°C) 
until centrifugation at 2500 g at 4°C for 5 min. Plasma samples were stored in 300 µL aliquots at -80°C 
until assayed for AG and UAG. After slowly thawing on water ice, all plasma samples were briefly 
cleared by centrifugation before transferring into the assay plates. All samples were analysed in 
duplicate (50µL/well) (9). A cubic polynomial fitting was used to determine concentrations from the 
calibration curves, resulting in r2 > 0.995 for all assays performed. Intra-assay coefficient of variation 
(%CV) is typically 2.7% CV for AG and 3.4% CV for UAG. Inter-assay % CV is 13.2% CV and 15.0% CV, 
for AG and UAG respectively (manufacturer’s suggested cut-off=25%).
STATISTICAL ANALYSIS 
Comparative analysis between groups was calculated by Mann–Whitney U tests and Wilcoxon’s 
signed rank test. Statistical analysis was performed using SPSS software (version 16 for Windows; 
SPSS, IBM, Armonk; NY; USA) and GraphPad Prism Version 6.04 (GraphPad Software; La Jolla; CA; 
USA). The results are expressed as median ± interquartile range (IQR). P-values of < 0.05 were 
considered statistically significant.
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RESULTS
Patient characteristics are shown in Table 1. Obviously, women with GDM had a significantly higher 
HbA1c, fasting and 2-hour post glucose load levels than pregnant women with NGT (P=0.001). 
Fasting median plasma AG levels in GDM (N=19) and NGT (N=19) were 11.5 pg/mL (IQR: 5.4–16.8) 
and 13.7 pg/mL (IQR: 10–25.6, P=0.456), respectively (‘reference levels’ of AG range from 22.7 to 
61.9 pg/mL) (9). Median 2-hour post OGTT plasma AG levels in GDM and NGT were 10.4 pg/mL 
(IQR: 2.7–13.9) and 10.2 pg/mL (IQR: 6.0–13.6, P=0.672), respectively. Fasting UAG median plasma 
levels in GDM and NGT were 44.6 pg/mL (IQR: 37.8–84.2) and 72.8 pg/mL (IQR: 39–146, P=0.320), 
respectively (‘reference levels’ of UAG range from 23.3–33.4 pg/mL) (9). Median 2-hour post OGTT 
UAG levels in GDM and NGT were 34.4 pg/mL (IQR: 26–49.3) and 46 pg/mL (IQR: 26.4–99.6, P=0.293) 
respectively. The fasting median AG/UAG ratios in GDM were 0.2 (IQR: 0.13–0.31), which were not 
significantly different from the median AG/UAG ratios in NGT 0.19 (IQR: 0.14–0.28), P=0.605). The 
2-hour post glucose load AG/UAG ratios in GDM and NGT were also similar 0.23 (IQR: 0.11–0.29) and 
0.19 (IQR: 0.14–0.28) P=0.736), respectively. 
Plasma AG concentrations decreased significantly 2-hour post OGTT in GDM (P=0.001) as well as in 
NGT (P=0.002) (Figure 1A). Plasma UAG also decreased significantly 2-hour post OGTT both in GDM 
(P=0.0001 and in NGT (P=0.0002) (Figure 1B). There were no significant differences in plasma AG/
UAG ratios post glucose load between GDM (P=0.776) and NGT (P=0.827). 
Table 1 | Patient characteristics 
Parameter GDM 
N=19
NGT 
N=19
P-value 
Age – yr 35 (30–38) 34 (29–37) 0.320
BMI – kg/m2 28.4 (25–35) 29.7 (25–35) 0.942
Pre-pregnancy BMI – kg/m2 28 (24–35) 29 (23.4–35) 0.827
First trimester glucose – mmol/L 5.1 (4.4–5.3) 4.7 (4.3–5.4) 0.428
Gestational age at blood collection – weeks 24 (24) 24 (24–25) 0.139
75-g OGTT: fasting glucose – mmol/L 5.3 (5.1–5.8) 4.6 (4.3–4.8) 0.001*
75-g OGTT: 2-hour glucose – mmol/L 8.8 (7.1–9.9) 6.2 (5.5–7.0) 0.001*
HbA1c – mmol/mol 35 (33–38) 31 (29–32) 0.001*
BMI: Body Mass Index; OGTT: Oral Glucose Tolerance Test 
Data are presented as median with inter-quartile range. *P < 0.05 was considered statistically significant. 
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Figure 1 | Ghrelin levels and response to oral glucose tolerance test 
(A) Plasma acylated ghrelin (AG) levels during OGTT in women with normal glucose tolerance (NGT) and 
gestational diabetes mellitus (GDM). Data are shown as median with interquartile range. * P=0.002, **P=0.001. 
(B) Plasma unacylated ghrelin (UAG) levels during OGTT in women with normal glucose tolerance (NGT) 
and gestational diabetes mellitus (GDM). Data are shown as median with interquartile range. * P=0.0002, 
** P=0.0001.
Discussion
In contrast to our hypothesis, and using a sensitive assay, plasma ghrelin levels were not lower in 
women with GDM compared to women with NGT. Ghrelin levels decreased significantly 2-hour post 
OGTT in both groups, which suggests that the physiological negative effect of oral glucose intake 
on ghrelin levels is still intact. These results indicate that ghrelin is not a useful biomarker in GDM. 
Our data are in agreement with the results of a study reported by Riedl et al. who found no association 
between fasting or post-load plasma ghrelin levels and reported that ghrelin suppression in GDM 
is not the result of insulin resistance. These authors suggest that ghrelin suppression is required 
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to allow the physiological insulin resistance necessary for growth and nourishment of the foetus 
(5). Another study by Telejko et al. found decreased ghrelin levels during pregnancy irrespective of 
glucose tolerance status (3). On the contrary, studies have indeed reported lower ghrelin levels in 
GDM compared to healthy pregnant women. For example, Palik et al. showed that serum AG levels, 
using a different assay than we did, were significantly lower in women with GDM versus NGT during 
the third trimester of pregnancy (10). 
Ghrelin levels appeared suppressed during pregnancy in comparison with reference levels 
from healthy non-pregnant individuals (9). Likewise, Tham et al. showed that ghrelin levels were 
suppressed relative to postpartum, using a similar assay (4). Furthermore, these authors showed 
that AG levels recovered after pregnancy, which implies that the low AG/UAG ratio is a result of 
pregnancy. 
Pregnancy is characterized by increased food intake, maternal weight gain and progressive insulin 
resistance. The orexigenic effects of ghrelin may contribute to the positive energy balance, while 
adipose tissue causes a negative feed-back regulation on ghrelin production (10). Ghrelin levels 
decrease with hyperglycaemia and hyperinsulinaemia, reflecting the inhibitory effect of insulin on 
ghrelin secretion (4). This hypothesis is supported by increased ghrelin levels during mid-pregnancy 
and decreased levels during late gestation (11). Whether low ghrelin levels are a risk factor or a 
compensatory mechanism, is unknown. 
The strength of our study was that we were able to measure both AG and UAG with a sensitive assay, 
but it has also some limitations. Firstly, comparing our results with other study outcomes is difficult 
because of the different assay techniques used. Secondly, a larger sample size might improve the 
reliability of the outcome, although our data show no suggestion of an association of ghrelin levels 
in early pregnancy with the development of GDM in the population of subjects studied. 
In conclusion, both AG and UAG levels are low during pregnancy regardless of the level of glycaemic 
control, and they decrease normally after an oral glucose load. 
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Abstract
Aim: To study the effect of metformin on the incidence of gestational diabetes mellitus (GDM) in 
pregnant women with a high risk of GDM. 
Methods: In this open-label randomized-controlled trial we randomly assigned 49 pregnant women 
with a high risk of GDM to receive metformin (N=24) at a dose of 2.0 g per day, or no intervention 
(N=25) from 14 weeks of gestation until delivery. The primary endpoint was the incidence of GDM in 
both groups. The secondary endpoints included maternal and neonatal outcomes.
Results: A total of eight women withdrew consent during the trial, which left 18 women in the 
metformin group and 23 in the control group. There were no significant between-group differences 
at baseline. We could not detect significant between-group differences in the incidence of GDM, 
large-for-gestational-age infants, or adverse maternal or neonatal outcomes. The rate of elective 
labour induction was higher in the control group than in the metformin group (72.7% vs. 38.9%, 
P=0.031). 
Conclusions: Metformin treatment of pregnant women from 14 weeks until delivery appears to have 
no influence on the incidence of GDM is this small population. No harmful effects of metformin use 
in pregnancy were observed. Long-term follow-up of children exposed to metformin in pregnancy 
is important for recruitment of women in clinical trials and in clinical practice. 
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Introduction
The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide (1). Attempts at 
reducing adverse pregnancy outcome through dietary and lifestyle interventions have shown 
modest effects, with no significant impact on GDM incidence and related outcomes (2-4). 
Metformin, a biguanide analogue, increases insulin sensitivity and decreases hepatic glucose 
production (5). Therefore, metformin might also reduce insulin resistance in pregnancy, leading 
to less maternal weight gain, a reduction in maternal glucose levels and subsequent foetal 
hyperinsulinaemia. In turn, this could have a positive effect on neonatal birth weight and the risk 
of obesity and diabetes later in life. Evidence thus far supports the safety and efficacy of the use of 
metformin during pregnancy, but there is still disparity in the acceptance of it as long-term outcome 
in children is unknown (6-9).
In women with polycystic ovary syndrome (PCOS) who used metformin in early pregnancy, reports 
on the effect on the incidence of GDM have been conflicting (10,11). 
To date, two large double-blind randomized-controlled trials (The EMPOWaR and The MOP Trial) 
showed no significant effect of metformin on birth weight percentile in obese pregnant women (12, 
13). We investigated the effect of metformin, not only in obese pregnant women, but also in women 
with other risk factors for GDM.
Methods
In this open-label randomized controlled trial, we randomly assigned women with a high risk to 
develop GDM to receive either metformin at 14 weeks of gestation or no intervention (control 
group). High risk was defined according to the Netherlands Society of Obstetrics and Gynaecology 
guideline and included: GDM in a previous pregnancy, body mass index > 30 (kg/m2) at the first 
prenatal screening, birth weight previous child > 4500 gram or > 95th percentile, first degree relative 
with diabetes mellitus, certain ethnic groups with a high prevalence of diabetes (e.g. Black, Asian, 
Hindu), history of unexplained intra-uterine foetal death, and history polycystic ovary syndrome 
(PCOS) (14). Eligible women were between 18 and 41 years old and were less than 14 weeks 
pregnant. Exclusion criteria included pre-gestational diabetes, no singleton pregnancy judged 
by ultrasonography, known cardiac insufficiency, known renal- and liver-disease. The local ethics 
committee NL48005.101.14 approved this study. All participants provided written informed consent. 
Clinical Trials.gov number NCT02275845.
Randomization & intervention 
Eligible women were randomly assigned, in a 1:1 ratio, with the use of a computer-generated 
randomization, to either the metformin- or the control group. Metformin was started at 14 weeks 
of gestation (500 mg per day in the first week and 1000 mg per day from the start of the second 
week and continued until delivery). Women with adverse events (AE), possibly related to the use 
of high-dose metformin were asked to take metformin in their maximal individual tolerated dose. 
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All subjects received a standard diet of 2000 calories per day with an adequate distribution of 
carbohydrates during the day, as recommended by the Netherlands Diabetes Federation (15). 
Procedures
At enrolment (< 14 weeks of gestation), blood samples were taken after an overnight fast to asses 
baseline hyperglycaemia and renal- and liver-function. We excluded patients with impaired renal 
function (urea > 6.6mmol/L, creatinine > 85 µmol/L), or liver function (bilirubin > 16 µmol, alanine 
transferase > 60 µmol, or high fasting glucose in first trimester (> 6.1 mmol/L). Maternal BMI (kg/m²) 
was recorded at enrolment.
Follow-up visits were scheduled at 16 (in case of previous GDM), 24, 28, and 32 weeks of gestation. 
During each visit maternal weight, blood pressure and adherence to treatment was recorded. Lack 
of adherence to treatment was defined as not taking metformin 1–3 times a week, 4–6 times a week, 
or > 6 times a week. All women underwent a 75-g oral glucose tolerance test (OGTT) at 24 weeks of 
gestation (or at 16 weeks in case of previous GDM); metformin was not taken on the day of the OGTT. 
Women with normal OGTT results continued with the study procedures. GDM was diagnosed based 
when one or more plasma glucose level was elevated (fasting plasma glucose ≥ 7.0 mmol/L and/or 
2-hour plasma glucose ≥ 7.8 mmol/L) (16). Women diagnosed with GDM were advised to continue 
on the assigned study group. In addition, they received insulin therapy if treatment targets (fasting 
< 5.3 mmol/L; 2-hour postprandial < 6.7 mmol/L) were not met within one week. In accordance 
with standard protocol elective labour induction was performed at 38 weeks of gestation in women 
requiring insulin therapy. 
Outcome measures
Patient demographics and clinical data were recorded at enrolment (< 14 weeks of gestation). 
The primary outcome was the incidence of GDM in both groups. Other maternal outcomes included 
gestational weight gain (which was defined by the difference in weight at enrolment and the last 
antenatal visit), insulin therapy, pregnancy-induced hypertension (PIH) (systolic blood pressure 
≥ 140 and diastolic blood pressure ≥ 90 mm Hg after 20 weeks of gestation, measured twice), 
preeclampsia (PIH + proteinuria of ≥ 300 mg/24 hours), and delivery by cesarean section (primary or 
secondary). Neonatal outcomes included intra-uterine foetal death (any foetal death before onset 
of labor or no signs of life in utero after 20 weeks of gestation), early pregnancy loss (< 20 weeks), 
gestational age at birth (weeks), birth weight (g), head circumference at birth (cm), length at birth 
(cm), pre-term birth (< 37 weeks), large for gestational age > 90th percentile (adjusted for parity), birth 
trauma (clavicle fracture and/or shoulder dystocia and/or brachial plexus injury), respiratory distress 
(respiratory support or supplemental oxygen), admission to neonatal intensive care unit (NICU), 
low 5-minutes Apgar score (< 7), neonatal hypoglycaemia (< 2.6 mmol/L ), and hyperbilirubinaemia 
requiring phototherapy. 
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Adverse events
Patients were instructed to contact the investigator in case of an AE. In that case, the time of onset, 
severity, treatment required and relation to the study treatment were recorded. A data safety 
monitoring board oversaw the study. All serious AEs were reported to the data safety monitoring 
board. 
Statistical analysis
Sample size calculation 
We estimated that 176 patients in each group would provide 80% power to detect a 50% reduction of 
GDM in the metformin group. The significance level of the test was targeted at α=.05. After allowing 
for an expected withdrawal of 10%, we calculated that we would need to recruit 400 patients (200 
per group). The primary endpoint (GDM incidence in both groups) was assessed by means of a chi-
square test. Comparisons between groups were performed with the independent T-sample test or 
Mann-Whitney U test. Categorical variables were tested with the use of chi-square or Fisher’s exact 
when the event counts were small. 
Results 
Study population
The study period was from October 2014 till February 2017. A total of 51 women with a high risk for 
GDM agreed to participate. Two women were excluded due to fasting glucose level > 6.1 mmol/L. A 
total of 49 women were included, 24 women allocated to the metformin group and 25 women to the 
control group. Unfortunately, 6 women in the metformin group were lost to follow up (two before 
start of metformin, three prior to 24 weeks of gestation, and one at 28 weeks of gestation). One 
subject in the control group was lost to follow up immediately after randomization. In addition, one 
subject in the control group had an early pregnancy loss. Maternal characteristics are shown in Table 
1. There were no significant differences at baseline between the metformin group and the control 
group. The maximum tolerated daily dose of 2 g metformin was reached in 21 (87.5%) of 24 women. 
Two subjects stopped metformin and in another subject the dose was lowered to 500mg bid, due to 
gastro-intestinal side effects. Metformin adherence was good in 14 (77.8%) women. Three subjects 
did not take metformin 1–3 times a week, none 4-6 times a week, and one subject forgot to take 
metformin more than 6 times a week. 
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Table 1 | Maternal characteristics and risk factors for GDM in early pregnancy 
Characteristic Metformin Group 
N=24
Control Group 
N=25
P-value*
Maternal age – (yr) 29.3 ± 5.2 30.7 ± 5.2 0.818
Maternal weight (kg) < 14 weeks gestation – kg 87.0 ± 18.0 81.5 ± 16.2 0.744
Body mass index – kg/m² 31.3 ± 5.8 30.0 ± 5.5 0.792
Length of gestation at enrollment – wk 11.7 ± 1.2 12.3 ± 1.4 0.500
Race or ethnic groupa
White 9 (37,5) 8 (32) 0.686
Black 6 (25) 9 (36) 0.404
Moroccan 4 (16,7) 3 (12) 0.476
Asian 1 (4,2) 0 (0) 0.490
Hindu 0 (0) 1 (4) 0.510
Otherb 3 (12,5) 3 (12) 0.646
Risk factors for GDM – no. (%)
GDM in previous pregnancy 5 (20.8) 10 (40) 0.146
BMI > 30 at first prenatal screening 14 (58.3) 13 (52) 0.656
Previous infant with birth weight > 4500 gram  
or > 95th percentile
0(0) 1(4) 0.322
First degree family member with diabetes mellitus 11 (45.8) 16 (64) 0.201
History of polycystic ovary syndrome 1 (4.2) 1 (4) 0.976
History of unexplained intra-uterine foetal death 1 (4.2) 1 (4) 0.976
75-g OGTT: fasting glucose – mmol/L 5.6 ± 0.8 5.6 ± 0.8 0.896
75-g OGTT: 2 hour glucose – mmol/L 8.2 ± 1.8 8.4 ± 1.6 0.646
Data presented as mean ± SD or frequency (%); aRace or ethnic group was self-reported; P-value < 0.05 was significant
Outcome measures
The incidence of GDM did not differ between the metformin group and the control group 
(10 (55.6%) vs. 16 (69.6%), P=0.355) (Table 2). The incidences of maternal outcome parameters 
such as PIH, preeclampsia, and cesarean section were similar in both groups. The rate of elective 
labour induction was significantly higher in the control group than in the metformin group 
(72.7% vs. 38.9%, P=0.031). Elective labour induction was performed at 38 weeks of gestation in 
women on insulin therapy or with uncontrolled hyperglycaemia. However, this did not result in a 
higher rate of secondary cesarean section. There was no significant difference between the groups 
in the incidence of other pregnancy complications or adverse foetal or neonatal outcome. 
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Table 2 | Maternal and Neonatal Outcomes 
Outcome Metformin Group 
N=18
Control Group 
N=23
P-value*
Maternal Outcomes 
Gestation diabetes mellitus – no. (%) 10 (55.6) 16 (69.6) 0.355
Insulin therapy – no. (%) 2 (20) 8 (50) 0.218
Pregnancy induced Hypertension – no. (%) 2 (11,1) 0 (0) 0.187
Preeclampsia – no. (%) 0 (0) 2 (8.7) 0.495
Gestational age at start insulin – (wk) 24 ± 9.8 24 ± 5.3 0.185
Gestational weight gaina – (kg) 6.5 ± 4.7 6.8 ± 4.7 0.733
Labour induction 7 (38.9) 16 (72.7) 0.031*
Cesarean section 7 (38.9) 10 (45.5) 0.676
Primary 4 (40) 3 (42.9) 0.646
Secondary 6 (60) 4 (57.1) 0.646
Foetal or neonatal outcomes 
Intra-uterine foetal deathb – no. (%) 0 (0) 0 (0)
Early pregnancy lossc – no. (%) 0 1 (4.3) 0.561
Male sex – no. (%) 9 (50) 14 (63.6) 0.385
Gestational age at birth – (wk) 38.8 38.5 0.807
Birth weight – (gr) 3052 ± 441,4 3251.8 ± 486,6 0.539
Head circumference at birth – (cm) 33.6 ± 1.1 34.1 ± 2.4 0.300
Length at birth – (cm) 49.28 ± 2.2 49 ± 2.0 0.763
Large for gestational aged – no. (%) 1 (5,6) 0(0) 0.450
Pre-term birth (37 wk) – no. (%) 0 (0) 2 (8.7) 0.495
Apgar score < 7 at 5 min – no. (%) 1 (5.6) 2 (9.1) 0.577
Admission to the NICU – no. (%) 0 (0) 1 (4.8) 0.538
Birth traumae – no. (%) 0 (0) 0(0)
Hyperbilirubinemia requiring phototherapy – no. (%) 0 (0) 1 (4.8) 0.538
Respiratory distress syndrome – no. (%) 1 (5.6) 2 (9.5) 0.559
Hypoglycaemia – (< 2.6 mmol/L) 1 (5.6) 2 (9.1) 0.667
Data presented as mean ± SD or frequency (%); a Gestational weight gain was defined as the difference in weight between the 
fist antenatal visit (< 14 week) and the last antenatal visit; b Intra-uterine foetal death is any foetal death before onset of labor or 
no signs of life in utero after 20 weeks of gestation; c Early pregnancy loss: death < 20 weeks of gestation; d Large for gestational 
age was defined by a neonatal birth weight that was higher than the 90th percentile; eBirth trauma included shoulder dystocia 
and/or clavicle fracture and/or brachial plexus injury; P-value < 0.05 was statistically significant.
Adverse events 
The incidence of Aes was higher in the metformin group but not significantly different (P=0.206) 
(Table 3). Most Aes were gastro-intestinal side effects related to the initiation of metformin. Two 
subjects stopped metformin (one due to hypoglycemia in combination with insulin and one due to 
gastro-intestinal effects). Two subjects temporarily stopped (maximum of 7 days) and one had doses 
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reduction to 500mg twice daily. The incidence of serious Aes (maternal and/or foetal) was higher 
in the control group (N=10 versus N=2) than in the metformin group but not significantly different 
(P=0.477). 
Table 3 | Adverse Events 
Category and event Metformin Group 
N=18
Control Group 
N=23
P-value* 
Serious adverse maternal events 0.477**
Hospitalization 
Abdominal trauma 1 0
Abdominal pain without diagnosis? 1 0
Threatening premature birth 0 1
hyperemesis gravidarum 0 1
hypovolemic shock due to placenta previa requiring 
cesarean section 
0 1
Preeclampsia requiring labour induction 0 1
Partus immaturesa 0 1
Surgery 
Wrist trauma due to accident 0 1
Herniation requiring laparoscopic surgery 0 1
Serious foetal or neonatal adverse events
Early foetal loss 0 1
Congenital malformations 
type III laryngomalacy 0 1
Neonatal infection requiring antibiotics 0 1
Other maternal adverse events 
Gastro-intestinal effects 9 3 0.206
Gastro-intestinal effects resulting in doses reductionb 1 0
Gastro-intestinal effects resulting in temporary treatment 
cessationc
2 0
Gastro-intestinal effects resulting in metformin cessationd 1 0
Hypoglycaemia in combination with insulin resulting in 
metformin cessatione
1 0
Other eventsf 2 4
a Early foetal loss at 18 weeks of gestation; b Doses reduced to 2d500mg from 20 weeks of gestation and continued until delivery; 
c One woman stopped metformin for 7 days and one woman for 3 days; d Stopped metformin at 20 weeks of gestation; e was 
used in combination with insulin, metformin stopped metformin at 35 weeks of gestation; f In the metformin group: headache 
(2x); control group: urinary tract infection (2x), pneumonia, asthma exacerbation; P-value < 0.05 was statistically significant; 
** Serious adverse maternal and foetal/neonatal events were compared together.
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Discussion
GDM is associated with significant maternal and perinatal morbidity. The prevalence of GDM 
is increasing in line with the obesity epidemic and causing considerable impact on health care 
services and economic burden. Therefore, the need for preventative strategies in women with 
high risk of GDM is vital. We hypothesized that metformin in women with high-risk factors, would 
reduce insulin resistance and would lead to a lower incidence of GDM. However, women in our 
study population were concerned about the effects of metformin use during pregnancy. Besides 
the general reluctance to take medication during pregnancy, the additional uncertainty about long-
term safety had a negative impact on recruitment, and resulted in insufficient power to properly 
address outcome parameters. In this small study in women with a high risk of GDM, metformin 
had no significant influence on GDM incidence thus far. Our data did show a clear trend towards 
fewer women requiring additional insulin therapy in the metformin group than in the control group 
(20% vs. 50%). In the Metformin versus Insulin for the treatment of Gestational Diabetes (MiG) trial, 
the percentage of women with additional insulin therapy was higher (46.3%) than in our study 
population, despite the fact that the groups were similar in terms of BMI, treatment targets, and 
metformin dosages (17). Reducing the number of women on insulin therapy could potentially result 
in less maternal weight gain, fewer pregnancy complications, and less burden on specialist care (12). 
In our centre, insulin therapy is an indication for elective labour induction at 38 weeks of gestation, 
which resulted in significantly more women undergoing elective labour induction in the control 
group. However, this did not result in a higher rate of cesarean section as has been confirmed in 
previous studies (18-20). To date, two large randomized-controlled trials (The MOP trial and The 
EMPOWaR trial) studied the effect of metformin in obese pregnant women without diabetes 
mellitus (12,13). The EMPOWaR trial randomized white women with a BMI > 30, to metformin at a 
dose of 2.5 g per day or placebo, between 16–18 weeks of gestation. Results showed no difference 
in median birth weight, maternal weight gain, preeclampsia or other adverse neonatal outcomes 
between groups. Similar to our study, this study also had a low rate of eligible women who agreed 
to participate (13%). The lack of effect on birth weight could be attributed to low adherence to 
an adequate dose of metformin. In the MOP trial, women of all racial groups with a BMI > 35 were 
randomized to metformin 3.0 g per day or placebo between 12 to 18 weeks of gestation. Metformin 
was not associated with a lower incidence of median neonatal birth weight. However, women in the 
metformin group did have less gestational weight gain and a lower rate of preeclampsia compared 
with placebo, but the power was not adequate to study the effect on metformin on secondary 
outcomes. Women in the MOP trial had a higher adherence to an adequate of metformin than in the 
EMPOWaR trial (66% vs. 38%). Both studies concluded that metformin should not be given to obese 
pregnant women with diabetes. Perhaps improved high risk identification is necessary to identify a 
sub-group who will most likely benefit from an early intervention. 
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Metformin in pregnancy
Early reports on the use of metformin during pregnancy date back from the 1970s (21). Since then, 
sound evidence has shown the safety and efficacy of metformin use in pregnancy (6-9). A landmark 
study by Rowan et al. randomized 751 women with GDM to receive either metformin or insulin. 
They reported no significant differences in the composite foetal outcome between groups. Women 
treated with metformin had less weight gain compared to women treated with insulin (17). 
Most data from metformin use in pregnancy has come from women with PCOS (11,22). One 
randomized controlled trial involving 273 women showed that metformin at 2.0 g per day or placebo 
in early pregnancy showed significantly less gestational weight gain than in the placebo group. 
However, there were no significant group differences in the rate of preeclampsia, GDM, preterm 
birth of birth weight (23). On the contrary, in a much smaller trial in women with PCOS, who received 
metformin at a dose of 1.7g per day, it was associated with a lower rate of preeclampsia (10). 
There have been concerns about the effect of metformin on the male reproductive system. A study 
in rodents suggested that metformin treatment during pregnancy may have harmful effects on 
testicular development in offspring (24). However, recently Tertti et al. showed that prepubertal 
testicular size did not differ between offspring born to metformin-treated mothers and those born 
to insulin-treated mothers (25).
Overall, the short-term safety has been shown and there might even benefits but long-term safety 
data remains an issue. Follow-up data (MiG TOFU trial) in 2-year-old children with foetal exposure 
to metformin or insulin had similar birth weights but those exposed to metformin showed lower 
visceral fat than those exposed to insulin. This suggests a healthier fat distribution (26). In another 
follow-up study by Ro et al., eight year old children who were exposed to metformin in utero, showed 
no differences in weight, height, body composition, and insulin resistance. However, these children 
did have higher fasting glucose levels and higher systolic blood pressure (27). Despite lack of long-
term safety going into adulthood, the National Institute for Health Care Excellence (NICE) guideline 
and the American College of Obstetricians and Gynecologists recommend the use of metformin in 
in GDM (28). 
In conclusion, in confirmation with the available literature we observed that the use of metformin 
during pregnancy seems to have no harmful maternal or neonatal effects. We also observed in 
a small study population of in women with high risk for GDM that the use of metformin had no 
significant influence on GDM incidence. However, studies selecting those with the highest risk are 
necessary to reveille existing differences. In any case, longer-term follow-up of children exposed to 
metformin in pregnancy is essential to increase the acceptance of metformin as treatment but also 
meet recruitment of women with high risk in future clinical trials.
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Abstract 
Background: Type 2 diabetes mellitus (T2DM) is encountered more frequently in women with a 
history of gestational diabetes mellitus (GDM). Screening for T2DM after pregnancy is, therefore, 
recommended every ≥ 1–3 years in this population. Early detection could allow for timely inter-
vention strategies, especially in women of childbearing age. Data on adherence to diabetes 
screening recommendations and the prevalence of T2DM in this population are not available in the 
Dutch population. 
Aim: To investigate the T2DM screening rate and evaluate the risk of T2DM in the five-year period 
following the GDM pregnancy. 
Methods: Single centre survey in 85 women diagnosed with GDM in 2010, using electronic medical 
records. Primary care physicians were asked to complete a survey regarding the screening frequency 
and the onset of T2DM within five years after GDM. 
Results: On average 33% underwent yearly screening. The screening rate, however, went up to 
61.2% after primary care physicians were requested to screen this population in 2015. Of the women 
who were screened 10 (19.2%) developed T2DM within 5 years after GDM. 
Conclusion: Current screening recommendations are poorly met, leading to missed, or delayed 
diagnosis of T2DM in our population. T2DM is a frequent occurring long-term complication in those 
who were screened in the five year period after delivery. Optimizing awareness amongst health care 
professionals of GDM as a risk factor for T2DM is warranted, and strategies to improve surveillance 
are necessary. 
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Introduction
Type 2 diabetes mellitus (T2DM) is a major public health problem of epidemic proportion. The 
increasing incidence of T2DM is attributed to a global rise in obesity, growing elderly population 
and improved screening methods. In 2030 an estimated 66.5 million people will be diagnosed 
with diabetes in Europe alone (1). Identifying high-risk populations is essential for the initiation of 
screening and prevention in daily practice. Gestational diabetes mellitus (GDM) is associated with a 
seven-fold increased risk for T2DM when compared to non-diabetic pregnancies (2). Furthermore, 
their offspring are at increased risk for developing obesity and T2DM later in life (3,4). Without 
appropriate screening, T2DM often remains undiagnosed with asymptomatic progression. This is a 
concern, especially in young women of childbearing age, as undetected hyperglycaemia may cause 
early foetal loss or congenital malformations in a subsequent pregnancy (5). Evidence shows that 
intervention with lifestyle adjustments and diet are cost-effective and may prevent or delay the onset 
of T2DM (6,7). However, 6–12 weeks postpartum screening rates are low with only 20–45% of women 
with a GDM pregnancy return for screening (8,9). Little is known about adherence to long-term 
yearly screening recommendations. In the Netherlands, annual T2DM screening is recommended 
in the first five years after the GDM pregnancy (10). No data on adherence to these screening 
recommendations are available. The aim of this study was to investigate the T2DM screening rate 
and determine the long-term risk of T2DM in the five years following the GDM pregnancy. 
Methods
We retrospectively analysed 85 women diagnosed with GDM in 2010 at the Maasstad Hospital, 
Rotterdam, the Netherlands. GDM was diagnosed when the fasting plasma glucose level was 
≥ 7.0 mmol/L and/or 2-hour plasma glucose ≥ 7.8 mmol/L after the 75-g oral glucose tolerance test 
(11). Patient baseline characteristics were obtained from electronic medical records (Table 1). Body 
mass index (BMI) (kg/m²) was determined in early pregnancy at the first visit to the obstetrics & 
gynaecology outpatient clinic. Insulin therapy was initiated in case dietary and lifestyle adjustments 
did not result in treatment targets (fasting glucose < 5.3 mmol/L and 2-hour postmeal < 6.7 mmol/L) 
(11). 
In the Netherlands, primary care physicians are responsible for yearly T2DM screening in women with 
a history of GDM. According to the Dutch College of General Practitioners, yearly screening (fasting 
glucose) is advocated for the five-year period directly following the GDM pregnancy and every three 
years thereafter (10). In accordance with these recommendations we conducted a survey in 2015 
among the primary care physicians of the 2010 cohort of 85 women with GDM. They were asked 
to verify two questions. 1) Did yearly T2DM screening (fasting glucose) during five years following 
the GDM pregnancy take place? 2) Was the woman diagnosed with T2DM in the five years following 
the GDM pregnancy? Diagnosis of T2DM was defined as: fasting glucose ≥ 7.0 mmol/L on two 
separate days, or fasting glucose ≥ 7.0 mmol/L or a random glucose ≥ 11.0 mmol/L in combination 
with symptoms associated with hyperglycaemia (10). If women had not been screened in 2015, then 
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the primary care physicians received a request to recommence T2DM screening. The percentage of 
T2DM in the five-year follow-up period was determined in those women who were screened every 
year (2010–2015) or in those who were only screened in 2015. 
Results
In total 85 women diagnosed with GD in 2010 were analysed. Maternal characteristics are shown in 
Table 1. The median age was 33 with a range from 28-37. The majority of women (76.5%) had a BMI 
> 25 in early pregnancy. The population is diverse in terms of ethnicity: about one third is Caucasian, 
while 1 out of 4 women were of north-African descent. Insulin therapy was required in 45.9% of 
cases. Diabetes mellitus in a first degree family member (58.8%) appeared to be a prevalent risk 
factor in our population. Patient characteristics during pregnancy of the women who developed 
T2DM are shown in Table 2. In the first four years of follow-up, 33% of the population was screened 
yearly. In 2015, when the primary care physicians were requested to recommence screening, the 
rate increased to 61.2%. In the population of women who were screened in the five year follow-up 
period, 10 (19.2%) developed T2DM and 42 did not. In the group that was not screened (N=33), 
11 women did not respond to screening invitation and 22 moved away, or changed primary care 
physicians or were lost to follow-up. 
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Table 1 | Patient characteristics 
Parameter No. (%)
Age (years)
< 25 4 (4.7)
25–35 47 (55.3)
35–45 33 (38.8)
> 45 1 (1.2)
Age 33 [28–37]
BMI (kg/m²) 7 missing
< 18,4 1 (1.2)
18,5–24 12 (15.4)
25–29 34 (43.6)
30–34 14 (17.9)
≥ 35 17 (21.8)
BMI 28.4 [26–33]
Race/ethnicity 6 missing
Caucasian 25 (29.4)
Negroid 11 (12.9)
Asian 2 (2.4)
Hindu 6 (7.1)
North-African 20 (23.5)
Turkish 9 (10.6)
Middle East 2 (2.4)
Other 4 (4.7)
First degree family member with DM 50 (58.8)
First trimester random glucose (mmol/L) 5.2 [4.6–5.6]
75-g OGTT: fasting glucose – mmol/L 5.7 ± 1.7
75-g OGTT: 2-hour glucose – mmol/L 8.7 ± 1.5
Gestational age at GD diagnosis (weeks) 28 [23–32]
Insulin therapy 39 (45.9)
BMI: body mass index; DM: Diabetes Mellitus; OGTT: oral glucose tolerance test; GDM: gestational diabetes mellitus
Data are presented as frequency (%), median [IQR] or mean ± SD. 
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Table 2 | Patient characteristics during pregnancy of women who developed T2DM 
Parameter T2DM 
(N=10)
No T2DM 
(N=42)
Age (years) 33 [31–40] 33 [29–38]
BMI (kg/m²) 32.1 [27–36] 28.5 [26-32]
Race/Ethnicity
Caucasian 3 (10) 17 (40.5)
Negroid 1 (10) 6 (14.3)
Asian 1 (10) 1 (2.4)
Hindu 1 (10) 2 (4.8)
North-African 2 (20) 9 (21.4)
Turkish 1 (10) 4 (9.5)
Middle East 1 (10) 2 (4.7)
Other 0 (0) 1 (2.4)
First trimester random glucose (mmol/L) 5.05 ± 0.75 5.5 ± 1.2
BMI: Body Mass Index; Data are presented as frequency (%), median [IQR], or mean ± SD. 
Discussion 
To our knowledge this is the first study, investigating adherence to long-term diabetes screening 
recommendations in women with a history of GDM in the Netherlands. Our study shows that the 
mandatory screening of women with GDM on the development of overt T2DM is suboptimal at 
best. Furthermore, T2DM was a frequent complication in those who were screened. Similar low 
screening rates have been reported before (12). Sending a reminder to the primary care physicians 
seems to have a significant effect on the screening rate, suggesting that reminders could help 
to accomplish higher screening rates. There are a number of explanations as to why long-term 
screening recommendations are not met. Post-partum screening studies have shown that women 
fail to return for screening (20–45% attendance) shortly after pregnancy (8,9). Reported barriers for 
postpartum screening included: limited time and other priorities such as childcare (13,14). If women 
with GDM do not attend post-partum screening programs, then they often remain out of ‘screening’ 
sight in the subsequent years after pregnancy. There are several explanations for the low long-term 
follow-up testing rates. Firstly, the lack of adequate transition of care from the endocrinologist 
and/or obstetrician during pregnancy to the primary care setting after delivery remains a pitfall in 
accomplishing proper screening. Secondly, conflicting screening programs on long-term follow-up 
frequency exist internationally, promoting ambivalence towards systematic screening (15,16). The 
American Diabetes Association recommends diabetes screening 6–12 weeks postpartum using 
OGTT and every 1–3 years thereafter (15). Women should be screened every 3 years if the results are 
normal; however, if impaired glucose tolerance or impaired fasting glucose is detected, screening 
should be done annually. The American College of Obstetrics and Gynaecology recommends 
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screening 6 weeks postpartum, but does not provide recommendations after this period (16). The 
Dutch Obstetrics and Gynaecology Association recommends screening 6 weeks postpartum and 
yearly screening thereafter, but no statement is made about the duration of follow-up (11). 
Finally, recognition and awareness of GDM as a risk factor for diabetes is not widespread among 
patients and health care providers. In a long-term follow-up study more than half of the women 
with a history of GDM reported that they had not been informed about their risk of T2DM (17). In 
a survey among women 3–5 years after their GDM pregnancy, less than half believed that it was 
“highly possible” or “very possible” that they would develop T2DM (18). Another survey showed that 
although almost all women with a history of GDM were aware of the risk for diabetes, only 16% 
believed that they were at risk as an individual (19). 
Improving screening rates is important for a number of reasons. First, early detection could allow for 
timely intervention. Lifestyle intervention and metformin reduced progression to T2DM compared 
with placebo by 35% and 40%, respectively (6). Additionally, considering the childbearing age of this 
population, it is important to aim for glycaemic control before future pregnancies. 
Since the number of screened women was relatively small, the risk of T2DM in our population should 
be interpreted with caution. Although T2DM is a frequent long-term complication in women with 
GDM, the percentage of T2DM in our population appeared to be lower than previously reported 
(20). However, our estimates are in line with more recent data from a systematic review showing 
a risk between 9.5% and 37% (3.5–11.5 years follow-up) (21). In our study, the risk of T2DM was 
determined in those women with a complete five-year follow-up or with T2DM screening in 2015. 
Theoretically, women with pre-gestational diabetes could have been included, however, since the 
first trimester screening showed normal random glucose levels this is less likely. The need for insulin 
therapy was higher in our population than previously described (22). This could be attributed to 
strict multidisciplinary management policy. Insulin therapy was initiated if glycaemic targets were 
not met in two consecutive days. Furthermore, obesity was highly prevalent in our population (23). 
Other limitations of this study include the retrospective design, and prepregnancy BMI was not 
available. 
Potential strategies to improve surveillance 
As education regarding the risk of T2DM during pregnancy will probably result in improved 
awareness and self-management after pregnancy, counselling women about long-term screening 
and raising awareness is clearly needed. Correspondence with clear screening recommendations 
from the gynaecologist or endocrinologist to the primary care physician is a vital step in the transfer 
of care. Subsequent registration of the GDM diagnosis in primary care medical record systems is 
important for the identification of women who should be screened for T2DM after pregnancy. If 
GDM is not registered in the international disease codes (International Classification of Primary Care 
– ICPC), or a high-risk label is given, then automatic yearly screening invites will not be generated and 
annual screening will likely not be performed. This is particularly worrisome in those patients who 
do not initiate screening themselves. Through registration in electronic medical records, screening 
could be implemented on a large scale by means of automated yearly reminders. Furthermore, 
uniformity in international long-term screening guidelines should be met for the implementation 
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of systematic screening. Several types of reminding systems have been investigated. Women prefer 
SMS reminding according to a questionnaire in Australian cohort. Postal and voice calls were the 
least preferred types (14). A systematic review investigated the effect of reminder systems for 
postpartum screening. Results showed that direct telephone calls strengthened the reminding 
effect on the women. Surprisingly, reminding both the primary care physician as well as the patient 
has not proven to be effective (24). A recent study showed that introducing a regional central 
coordinator to remind women both in writing and verbally improved post-partum screening rates 
to 75% (25). Furthermore, identifying those women who are at greatest risk of developing diabetes 
postpartum would allow for better individual education during pregnancy. Maternal age, obesity, 
insulin therapy, highest fasting glucose level (4th quartile vs. 1st quartile range), severity of glucose 
intolerance and a previous GDM pregnancy have been reported to be predictive factors for the 
development of T2DM (26,27).
In summary, current screening recommendations appear to be largely unsuccessful, leading to 
missed diagnoses of T2DM in women of childbearing age. T2DM is a frequent long-term complication 
in those women who were screened. Optimizing awareness amongst health care professionals of 
GDM as a risk factor for T2DM is warranted and strategies such as systematic reminder systems are 
necessary to improve surveillance. 
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Discussion & future perspectives
This thesis tries to address the overall management of gestational diabetes mellitus (GDM). We 
investigated the role of biomarkers and risk stratification, evaluated current management, and 
performed long-term follow-up in women with a history of GDM. This chapter discusses the main 
findings of this thesis, explores clinical implications, and provides recommendations for future 
research. 
Biomarkers and risk stratification
The overall incidence of GDM is increasing worldwide in part due to the increasing incidence of 
obesity and advanced maternal age (1). Epidemiological, clinical and experimental studies have 
shown that adverse exposures during foetal development, (over- and under nutrition) are associated 
with increased susceptibilities for many adult diseases (2-4). This creates a vicious cycle in which 
children exposed to hyperglycaemia in utero may be more likely to develop obesity and metabolic 
diseases later in life, and pass on the adverse environmental exposure to the next generation (5,6). 
Therefore, pregnancy offers a window of opportunity to not only reduce or prevent GDM and related 
complications but it also has potentials to prevent intergenerational transfer of adult diseases such 
as diabetes and cardiovascular disease. The increasing prevalence, long-term implications and rising 
overall health care costs, make GDM a public health concern (7). 
While current screening practices are largely based on the presence of maternal risk factors, in 
practice they fail to adequately identify all women with GDM (8,9). Moreover, recent prospective 
data has shown that diagnosis of GDM is preceded by foetal overgrowth occurring between 20–28 
weeks’ gestation, and that this is exacerbated by maternal obesity. This provides rationale for early 
pregnancy risk stratification and preventative strategies to ultimately prevent GDM and adverse 
outcome (10). 
GDM is increasingly being recognised as an inflammatory condition (Chapter 2). Cytokine production 
by macrophages in the adipose tissue affects post receptor insulin signalling. This disturbance of 
insulin signalling results in increased insulin resistance (11). Prospective studies have shown that 
a down-regulation of anti-inflammatory cytokines (i.e. adiponectin) and up-regulation of pro-
inflammatory cytokines (i.e. tumour necrosis factor- alpha, interleukin -6) are linked to GDM (12,13). 
Adiponectin appears to be one of the most promising candidates in the prediction of GDM (14). 
The addition of biomarkers to current screening models, which precede hyperglycaemia, might 
improve predictive value. Data from the largest study to date, investigating biomarkers and clinical 
risk prediction tools, showed that previous GDM, age, systolic blood pressure, sum of maternal 
skinfold thicknesses and anthropometric ratios (waist:height and neck:thigh) showed good 
discrimination (AUC 0.71, 95% CI 0.68–0.74). This improved with addition of candidate biomarkers 
to 0.77 (95% CI 0.73–0.80) (P < 0.001). Candidate biomarkers contributing to this model were HbA1c, 
glucose, fructosamine, triglycerides, adiponectin and sex hormone binding globulin (15). 
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Overall, evidence thus far remains contradictory due to difference in study designs, assay 
methods, diagnostic criteria for GDM, and certain confounders. The clinical implementation of 
clinical prediction models with biomarkers will depend on the additional predictive value, cost-
effectiveness and reduction of pregnancy complications. Prospective studies are warranted to 
confirm that biomarkers are independently associated with GDM risk. We are currently undertaking 
a study entitled “Adipokines in the Prediction of GDM”. The first aim of this study is to examine 
the association of adiponectin levels and the risk of developing GDM. Secondly, if adiponectin is 
associated with GDM, then we aim to investigate the additional predictive ability of adiponectin in a 
clinical risk prediction tool (ethnicity, family history, history of GDM and body mass index) based on 
a previous study by van Leeuwen et al. (16).
 In the process of further unravelling the pathophysiology of GDM, biomarkers associated with 
insulin resistance are to be explored. To date, the value of acylated ghrelin (AG) and unacylated 
ghrelin (UAG) as biomarkers in GDM was unknown. Ghrelin is a stomach-derived peptide discovered 
in 1999 as the endogenous ligand for growth hormone secretagogue-receptor (GHS-R) (17). Ghrelin is 
involved in a wide range of biological functions including glucose homeostasis (18). We investigated 
the potential role of ghrelin as a biomarker in GDM, using a double-antibody sandwich ELISA 
(Chapter 3). We hypothesized that ghrelin levels would be lower in women with GDM as a result of 
hyperinsulinaemia and increased insulin resistance. Contrary to our hypothesis, we demonstrated 
that ghrelin levels did not differ between women with GDM and normal glucose tolerance. Ghrelin 
levels decreased post oral glucose load showing a physiological response. Other reports have yielded 
conflicting results, with some presenting decreased ghrelin levels while others showed no effect of 
GDM on ghrelin levels (19-23). However, most studies measured total ghrelin, without differentiating 
between AG and UAG (24). We concluded that ghrelin is not a useful biomarker in GDM. 
Evaluating current management of gdm 
Maternal and Neonatal Outcomes 
The national guideline “Diabetes and Pregnancy” for screening and treatment of GDM was 
introduced by the Dutch Society of Obstetrics and Gynaecology in 2010 (25). In the period 2010 to 
2015, we observed a five-fold increase in the number of women treated for GDM at the Maasstad 
Hospital diabetes outpatient clinic. This is most likely due to the implementation of the guideline 
and ongoing sociodemographic changes. In light of this, we performed an analysis of pregnancy 
outcomes in women treated for GDM between 2010 and 2015 in a large multi-ethnic cohort in 
Rotterdam (Chapter 4). The aim was to evaluate maternal and neonatal outcomes and identify 
factors associated with neonatal complications. We showed that the current national screening and 
treatment guideline achieved a well-controlled GDM population with low rate of adverse pregnancy 
outcomes. One could argue that we assessed treatment outcomes in a more ‘T2DM’ population 
rather than a GDM population based on the relatively ‘outdated’ WHO 1999 diagnostic criteria (75-g 
OGTT fasting glucose ≥ 7.0 mmol/L; 2-h glucose level ≥ 7.8 mmol/L) (26). In this population with 
higher levels of hyperglycaemia one might expect higher rates of adverse pregnancy outcomes. 
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However, treatment targets (fasting < 5.3 mmol/L, 2-h postprandial glucose level < 6.7 mmol/L) 
were according to current international guidelines which might explain low incidence of adverse 
outcomes (25). 
Obesity and insulin therapy were independently predictive of neonatal complications. Our GDM 
pregnancy outcomes are in line with the results of several systematic reviews showing that treatment 
of GDM results in lower rates of adverse outcomes (27-29). The rate of large-for-gestational-age (LGA) 
(8.5%) infants was low but similar to other landmark treatment trials (30,31). Overall differences in 
pregnancy outcomes can be attributed to different GDM diagnostic criteria and definition of LGA 
used in other studies. Moreover, weekly monitoring and strict initiation of insulin therapy might 
also contribute to a low rate of adverse outcomes in our study. In contrast, Koning et al. reported 
a higher proportion of LGA infants (19.9%) despite using the same LGA definition (adjusted for 
age, parity and ethnicity) and treatment guideline (32). Firstly, women with GDM in their cohort 
were slightly more obese (38.2% vs. 33.9%) compared with our GDM population. Secondly, authors 
used a 1-hour postprandial glucose target (< 7.8 mmol/L) instead of a 2-hour postprandial glucose 
target (< 6.7mmol/L). Thirdly, although the overall labour induction rate (38 + 0 and 39 + 0 weeks 
of gestation) was higher in their cohort; they did not perform labour induction in all women with 
insulin therapy. 
The rate of labour induction was also higher in our population compared to the general obstetric 
population. In our cohort women who were treated with insulin therapy underwent elective labour 
induction between 38 + 0 and 39 + 0 weeks of gestation. Current delivery management is based 
(elective induction compared with expectant management) on one randomized-controlled trial (33). 
Results from the GINEXMAL trial will provide additional evidence as to whether or not, in women 
with GDM, induction of labour between 38 + 0 and 39 + 0 weeks is an effective management to 
improve maternal and neonatal outcomes (34). 
Adoption of the IADPSG diagnostic criteria: is it time?
The current diagnostic criteria for GDM are based on the World Health Organization (WHO) 1999 
criteria (75-g OGTT: fasting glucose ≥ 7.0 mmol/L; 2-h postprandial glucose ≥ 7.8 mmol/L) (26). Our 
results indicate that the rate of adverse pregnancy outcomes under the current national screening 
and treatment guideline is low. This is an important finding given the current discussion regarding 
the adoption of the more stringent diagnostic criteria, as proposed by the International Association 
of Diabetes and Pregnancy Study Groups (IADPSG) (75-g OGTT: fasting glucose ≥ 5.1 mmol/L; 1-h 
glucose level ≥10.0 mmol/L; and 2-h postprandial glucose ≥ 8.5 mmol/L) (35). These criteria have 
been endorsed by global health organizations in recent years (36,37). 
Critics opposing the IADPSG criteria suggest that these strict criteria lead to ´over-estimation’ of the 
prevalence (~20%), resulting in unnecessary medicalisation of pregnancy. Furthermore, they state 
that evidence for the association between these glycaemic levels and complications is weak (38,39). 
Arguments in favour suggest that considering the adverse metabolic alterations in utero caused by 
impaired glucose metabolism, more stringent criteria are necessary (2). Furthermore, other criteria 
failed to address the link between the worldwide increasing prevalence of glucose intolerance, 
T2DM and GDM. The National Health and Nutrition Survey (NHANES) in 2005–2008, showed that 
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30% of women in childbearing age in the U.S. have impaired glucose metabolism, suggesting 
that de IADPSG prevalence estimate is not so high after all (40). Careful consideration must go into 
adapting current guidelines, as the adoption could overwhelm health care services and increase 
economic burden (41). The IADPSG criteria will identify a GDM population with mild hyperglycaemia. 
However, we cannot automatically translate the proven treatment benefits to this new population 
(42,43). Currently, there are no evidence-based principles regarding the management of these 
additional women with GDM. Do the same management guidelines apply? Would dietary and 
lifestyle counselling be sufficient? Furthermore, the treatment of women with ‘mild’ hyperglycaemia 
may increase the risk of maternal hypoglycaemia and foetal undernourishment, which in turn might 
increase the risk of metabolic disorders in adult life (4,44). Controversy regarding the screening and 
management of GDM will remain until sound evidence from intervention studies is provided. 
To date, retrospective analysis and observational studies have shown potential benefits of treating 
mild hyperglycaemia (45). Future recommendations include large well-designed prospective trials 
including cost-effectiveness before guidelines are revised (46). Furthermore, the IADPSG criteria 
would only be cost-effective if linked to aggressive postpartum follow-up with intense diet and 
lifestyle management to reduce future risk of type 2 diabetes mellitus (T2DM) (41). 
Obesity
More than a third of our GDM population was obese in the first trimester of pregnancy. Obesity 
was the second most prevalent risk factor for GDM and independently associated with the 
neonatal complications. Meta-analysis showed an unadjusted OR for developing GDM of 2.14 
(95% CI 1.82–5.53), 3.56 (3.05–4.21), and 8.56 (5.07–16.04) in overweight, obese and severely obese 
women respectively compared to normal weight pregnant women (47). Obesity is associated with 
increased risk of significant adverse maternal and neonatal outcomes (48). Data from the HAPO study 
showed that the rate of macrosomia (birth weight > 4000 g) was twice as high in GDM compared 
to non-GDM in women with and without obesity. Obesity and GDM are therefore considered 
independent predictors of macrosomia. Furthermore, children born from obese mothers show 
higher rates of admission to the neonatal department tend to be large for gestational age and their 
lifetime risk of obesity and T2DM is increased (49-51). Prevention and strategies to reduce obesity, 
especially in women of childbearing age, are needed to overcome this vicious cycle. Interventions 
in pregnant obese women have shown little effect on GDM and the incidence of LGA infants (52-54). 
Perhaps risk stratification in obese women is necessary to identify a group that will most likely benefit 
from intervention. Furthermore, we suggest that women of childbearing age are offered evidence-
based and personalised lifestyle- and nutrition intervention before the pregnancy period (55,56). 
For example, a program such as the mobile health coaching program www.SmarterPregnancy.co.uk 
(Dutch version www.SlimmerZwanger.nl) is presented as an opportunity to promote preconception 
health (57). This should be implemented to support healthcare professionals in delivering ‘nutrition 
and lifestyle care’ in routine patient care (58). Further awareness about preconception health should 
be promoted through government programs and campaigns. 
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Monitoring of treatment 
Monitoring the effect of treatment during pregnancy is essential for pregnancy outcomes to be 
improved. Current practice consists of self-monitoring of blood glucose by means of finger-stick 
blood glucose measurements (59). We evaluated current monitoring of treatment in women with 
GDM (Chapter 5). In this study, we showed that blinded continuous glucose monitoring (CGM) 
detected hyperglycaemia in women with a normal self-monitoring of blood glucose profile. The 
percentage of time in hyperglycaemia detected by blinded CGM was however, not circumstantial. 
Due to study design and sample size, the clinical value of CGM versus SMBG, for improving pregnancy 
outcome could not be assessed. Recent evidence from the CONCEPTT trial showed that CGM during 
pregnancy in patients with type 1 diabetes was associated with improved neonatal outcomes (60). 
We suggest that in order to advance treatment monitoring research, uniformity in CGM parameter 
analysis should be reached (61). Results from the GlucoMoms trial might give more insight into the 
role of blinded CGM in women with insulin-treated GDM. However, investigators used intermittent 
blinded-CGM for brief periods during pregnancy, which raises the question of whether the effect 
on pregnancy outcome will be adequately studied (62). Future study recommendations should 
also focus on the evaluation of technological innovations. Technological innovations such as 
telemedicine (health services at a distance using a range of technologies) and personalized and 
interactive apps/mobile health programs present opportunities to improve accuracy, efficiency, 
patient satisfaction and economic benefit (63). At this point there is insufficient evidence to pose 
that telemedicine might improve pregnancy outcome in women with GDM but no harmful effects 
have been described either (64). Upcoming results from RCTs will most likely provide the first robust 
answer of the potential for integrated remote monitoring system in women with GDM (65,66). 
Pharmacological prevention of GDM 
The prevention of hyperglycaemia during pregnancy can have several positive effects: a reduction in 
short-term pregnancy complications, a reduced risk of long-term sequelae for mother and child, 
and a decrease in the economic burden (67).  In view of the striking increase in obesity, women 
with a high risk of GDM become the ideal group for targeting primary prevention strategies. To date, 
attempts at reducing the incidence of GDM have focused on dietary and lifestyle intervention, but 
have been largely unsuccessful (52,54,68-70). 
Metformin, a biguanide analogue, decreases hepatic glucose production and improves insulin 
sensitivity by increasing peripheral glucose uptake and utilization. Most data of the effect of 
metformin on pregnancy outcome has come from women with polycystic ovary syndrome (PCOS) 
(71,72). Data has shown conflicting evidence for the effect of metformin on the incidence of GDM 
and pregnancy outcomes (72-76). 
We investigated the effect of metformin in women with a high risk of GDM (Chapter 6). High 
risk was defined according to the screening criteria provided by the national guideline (25). Our 
hypothesis was that metformin in early pregnancy (started at 14 weeks of gestation) would reduce 
the progressive insulin resistance and subsequent onset of GDM. In this small study, the rate of GDM 
in both groups was not significantly different but groups were too small to draw sound conclusions. 
However, we observed no harmful effects of metformin use in pregnancy on either mother or child. 
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Two outcomes were of particular interest. Firstly, the rate of elective labour induction was significantly 
higher in the control group than in the metformin group. Elective labour induction was performed 
at 38 weeks of gestation in women requiring insulin therapy or with uncontrolled hyperglycaemia. 
However, this did not result in a higher rate of secondary caesarean section or other adverse neonatal 
outcomes. Secondly, although the study groups were small, our data did show a clear trend towards 
fewer women requiring additional insulin therapy in the metformin group than in the control group 
(20% vs. 50%). Besides the reluctance among pregnant women to take medication in general, the 
additional uncertainty about long-term safety of metformin use on offspring had a negative impact 
on recruitment. A study examining the use of metformin throughout pregnancy in 109 women with 
PCOS found normal growth and motor development in infants at 18 months old (77). The MiG-TOFU 
trial evaluated body composition in 2-year old children who were exposed to metformin and/or 
insulin during pregnancy. Authors reported a more preferable body fat distribution in children 
exposed to metformin, but total or body fat percentage was the same in both groups (78). Follow-up 
studies evaluating in the effect of metformin into adolescence and adulthood are urgently needed. 
Two recent RCTs studying the effect of metformin in specifically non-diabetic obese pregnant 
women concluded that, metformin had no effect on the incidence of GDM and birth weight (53, 
79). In the MOP trial, metformin was associated with less gestational weight gain and a lower rate of 
preeclampsia (79). The lack of effect on birth weight, despite lowering maternal glucose levels might 
raise the question whether other factors besides maternal hyperglycaemia drive neonatal adiposity. 
Catalano et al. suggests that excess maternal lipids might play an important role in foetal adiposity, 
particularly in the presence of maternal obesity (80). Perhaps inflammatory markers are facilitating 
foetal fat accumulation? Other mechanisms besides maternal hyperglycaemia, resulting in foetal 
adiposity and metabolic dysfunction should be investigated.
Overall, further research is warranted to identify the effective means of lifestyle modification 
and/or pharmacologic intervention, both in the pre-conception period and during pregnancy. 
Moreover, prediction tools to identify a sub-group within the high-risk population whom are most 
likely to benefit from early intervention are needed. 
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Postpartum and beyond
Type 2 diabetes mellitus screening 
Undetected hyperglycaemia postpartum could also lead to an increased risk of congenital 
malformations or early pregnancy loss in a subsequent pregnancy (81). Furthermore, hyperglycaemia 
during early stages of foetal development may cause a predisposition to long-term pathology in 
offspring creating a vicious cycle (2,82). Glucose intolerance resolves after pregnancy in most women, 
but the risk of developing T2DM is estimated at 50%–70% in the 5–10 years after delivery (83). 
Lifestyle interventions may prevent or delay the onset of T2DM and provide opportunity for early 
initiation of treatment and prevention of complications (84,85). Therefore, postpartum and long-
term T2DM screening is advised in this population. 
In clinical practice, the loss of women with GDM to follow-up screening after delivery is a significant 
problem (86). According to the Dutch College of General Practitioners, yearly diabetes screening is 
recommended in the first five years after a GDM pregnancy (87). In our follow-up study we showed 
that only about a third of the population was screened annually during the first five years after 
pregnancy (Chapter 7). However, sending a reminder to the general practitioners had significant 
impact on the screening rate. Of the women who were screened annually, about 20% developed 
T2DM in the five years after GDM. Similar low screening rates were reported by Koning et al. (88). Our 
results indicate that awareness about GDM as a risk factor for T2DM is low amongst both women and 
health care providers. Suggestions to improve diabetes screening rates include: correspondence 
with clear screening recommendations from the endocrinologist to the general practitioner and 
implementing track systems with automated yearly screening invites. Furthermore, women should 
be counselled about their risk of diabetes during pregnancy and be advised to also take own 
responsibility for screening. 
Identification of those with the highest risk might allow for better risk-stratification in daily practice. 
Various risk factors for postpartum diabetes, including age, glucose level in pregnancy, insulin 
treatment, family history of diabetes and obesity were identified in previous studies (89). Furthermore, 
there is mounting evidence that breastfeeding has short- and long-term health benefits for mothers 
with GDM. Results of observational studies and a small number of prospective studies suggest that 
breastfeeding is associated with improvements in glucose and lipid metabolism together with 
reduced risk of T2DM in women with GDM (90). Training, education, and support should be provided 
to promote breastfeeding among women with GDM. 
The Diabetes Prevention Program outcomes study (10-year follow-up) showed that in women with 
a history of GDM, intense lifestyle intervention and metformin reduced progression to diabetes 
compared with placebo by 35% and 40%, respectively (84). A strong determinant of the success was 
the availability of personal exercise trainers, but these require considerable financial resources. 
Maternal BMI and pregnancy-induced hypertension are also associated with on the future health 
of the women and their offspring. Postpartum lifestyle interventions focussed not only at glucose 
intolerance, but also weight and blood pressure appears necessary (91).
In conclusion, surveillance strategies should be improved and women with postpartum glucose 
intolerance should be offered an intervention. 
521779-L-bw-Brink
Processed on: 22-8-2018 PDF page: 107
107Discussion | 
8
Future research recommendations include performing studies that prospectively compare different 
strategies to improve patient and doctor adherence with screening recommendations. Specifically, 
investigating what the most effective health information technology intervention is. 
Conclusion 
In conclusion, in this thesis we have shown that ghrelin is not a useful biomarker in gestational 
diabetes mellitus. The treatment of GDM according to the current national guideline is successful 
in achieving a low rate of adverse pregnancy and perinatal outcome. Blinded continuous glucose 
monitoring showed limited additional diagnostic value compared with self-monitoring of blood 
glucose in women with well-controlled GDM. Metformin in women with a high risk of GDM showed 
no effect on GDM incidence but larger studies are needed, no harmful effects have been observed 
thus far. We have also demonstrated that current long-term type 2 diabetes screening in women 
with GDM is suboptimal and that improved surveillance strategies are necessary.
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Gestational diabetes mellitus (GDM) is one of the most common metabolic disorders during 
pregnancy. The number of pregnancies complicated by GDM is increasing in line with the obesity 
epidemic. Advanced maternal age, certain ethnicities (e.g. Asian, Caribbean), family history of 
diabetes mellitus, GDM in a previous pregnancy and obesity are among others risk factors for 
developing GDM. Untreated GDM leads to increased risk of maternal and perinatal complications 
such as preeclampsia, caesarean section, pre-term birth, excessive birth weight (> 4000 gram), 
neonatal hypoglycaemia, and neonatal jaundice. Moreover, women with a history of GDM are at 
increased risk of developing type 2 diabetes mellitus and cardiovascular disease after pregnancy. 
Children born from mothers with GDM have higher chances of developing obesity and type 2 
diabetes mellitus. In general, GDM is diagnosed between 24–28 weeks of pregnancy by means of a 
75-g oral glucose tolerance test. Treatment consists of dietary and lifestyle advice. If these measures 
fail to achieve glycaemic goals,  insulin  is  initiated.   The importance of treating women with GDM 
is now widely accepted and has led to a reduction in serious pregnancy complications. Consensus 
regarding screening methods is still lacking. 
GDM is an emerging area of research and many questions regarding pathophysiology, prevention, 
management and long-term follow-up remain unanswered. 
Firstly, understanding the pathophysiology of GDM is essential for identifying mothers at risk, 
implementing preventative strategies and providing optimal management. However, in current 
antenatal care, understanding of pathophysiology of GDM is limited. Current risk prediction 
is mostly based on maternal history and clinical risk factors and may not optimally identify 
high risk pregnancies. Exploring the pool of biomarkers could advance understanding of GDM 
pathophysiology and explore risk prediction. Secondly, there is ongoing (inter)national debate 
regarding the adoption of the more stringent International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) diagnostic criteria, which have been endorsed by several international 
organisations, but have not been implemented in the Netherlands. In light of this, we investigated 
pregnancy outcomes in women screened and treated according to the current Dutch Society of 
Obstetrics and Gynaecology guideline “Diabetes and Pregnancy” which was implemented in 2010. 
We also aimed to investigate whether the current treatment monitoring technique by means of self-
monitoring of blood glucose was sufficient for the detection of hyperglycaemia in women treated 
for GDM. Thirdly, while we have put extensive effort into managing glucose levels during pregnancy, 
less effort and success has been realized in achieving postpartum and long-term diabetes screening. 
The national guideline recommends diabetes screening postpartum and annually in the five years 
following the GDM pregnancy. Data on adherence to these screening recommendations was not 
available for the Dutch population. 
This thesis aimed to investigate the overall management of GDM including: biomarkers and risk 
stratification, evaluating current management, and long-term follow-up of women with GDM. 
In part I of this thesis we will explore the literature on GDM and biomarkers, to enhance under-
standing of pathophysiology and explore risk prediction, with a goal to ultimately promote 
prevention of GDM. 
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In Chapter 1 we provide the background and introduction of this thesis.
In Chapter 2 we give an overview of the literature regarding the potential role of biomarkers in 
the prediction of GDM. Low-grade inflammation and insulin resistance are exacerbated in women 
with GDM. Studies have shown that GDM is linked to the down-regulation of adiponectin and anti-
inflammatory cytokines (e.g., IL-10) and up-regulation of leptin and pro-inflammatory cytokines 
(e.g., IL-6 and TNF-α) implicated in insulin resistance. Integrated assessment in early pregnancy with 
a prediction model based on biomarkers & clinical parameters may enhance identification of high 
risk pregnancies. We are currently investigating the association between adiponectin and GDM and 
aim to evaluate the addition of adiponectin in a clinical risk prediction rule for GDM. 
 
In Chapter 3 we studied ghrelin levels in pregnant women with GDM and normal glucose 
tolerance, using a double anti-body sandwich ELISA kit. Ghrelin plays an important physiological 
role in modulating growth hormone secretion, insulin secretion and glucose metabolism. Our 
hypothesis was that women with GDM have more insulin resistance and hyperinsulinaemia with 
subsequently lower ghrelin levels than women with normal glucose tolerance. Contrary to our 
hypothesis, ghrelin levels did not significantly differ between women with GDM and normal glucose 
tolerance. Furthermore, ghrelin levels decreased significantly after oral glucose ingestion, showing 
a physiological response. These results indicate that ghrelin levels are not affected by GDM. This 
implicates that ghrelin levels are not useful as a predictive biomarker of GDM.
In part II of this thesis we evaluated current management of women with GDM. 
In chapter 4 we studied maternal and neonatal outcomes in a large multi-ethnic cohort in Rotterdam. 
We compared this GDM cohort with a general obstetric population (no pregestational diabetes or 
GDM) obtained from the National Perinatal Registry. We showed that BMI ≥ 30, OGTT levels (fasting 
and 2-h), GDM in a previous pregnancy and (Mediterranean) ethnicity were independent predictors 
for the need of insulin therapy. We also showed that obesity and insulin therapy are independently 
predictive of an increased risk of neonatal complications. The rate of labour induction was relatively 
high without leading to increased rates of caesarean section. Perhaps this contributed to the 
striking low rate of large-for-gestational-age infants. Overall, we concluded that the current national 
screening and treatment guideline achieved a well-controlled GDM population with low rate of 
adverse pregnancy outcomes. 
The goal in treating GDM is to reach normal glucose levels and reduce the risk of related adverse 
pregnancy outcomes. Current monitoring of treatment is performed by self-monitoring of blood 
glucose (SMBG). In chapter 5 we evaluated the potential of blinded continuous glucose monitoring 
(CGM) for the detection of high glucose levels (hyperglycaemia) in women treated for GDM. We 
observed that blinded CGM improved the detection of hyperglycaemia slightly compared with 
SMBG but the duration was not circumstantial. 
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In chapter 6 we investigated the effect of metformin in women with a high risk of GDM. Our 
hypothesis was that metformin in early pregnancy would reduce insulin resistance and subsequently 
the incidence of GDM. Due to recruitment problems we were not able to study the primary outcome 
but we observed no harmful effects of in women and offspring. Long-term follow-up in children 
exposed to metformin in pregnancy is necessary for widespread acceptance by clinician’s and 
patients. 
In part III we evaluated long-term diabetes screening recommendations. 
In Chapter 7 we studied long-term follow-up of women with GDM in the primary care setting. 
The aim was to evaluate diabetes screening in the five years following the GDM pregnancy. We 
demonstrated that only about a third of the women are screened annually after pregnancy. After 
sending a reminder to the general practitioners, the screening rate nearly doubled that year. 
Optimizing patient and healthcare provider awareness is necessary and improving surveillance 
strategies is warranted. 
In the general discussion we interpret the findings of the studies described and their implications for 
clinical practice Chapter 8. We also provide perspectives for future research. 
Conclusion 
In this thesis we have shown that ghrelin is not a useful biomarker in gestational diabetes mellitus 
(GDM). The treatment of GDM according to the current national guideline is successful in achieving 
a low rate of adverse pregnancy and perinatal outcome. Blinded continuous glucose monitoring 
showed limited additional diagnostic value compared with self-monitoring of blood glucose (SMBG) 
in women with well-controlled GDM. Metformin in women with a high risk of GDM showed no effect 
on GDM incidence but larger studies are needed, no harmful effects have been observed thus far. 
We have also demonstrated that current long-term type 2 diabetes screening in women with GDM 
is suboptimal and that improved surveillance strategies are necessary.
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Zwangerschapsdiabetes wordt definieert als verhoogde bloedglucosewaarden die voor het eerst 
tijdens de zwangerschap worden ontdekt. Zwangerschapsdiabetes komt ongeveer in 1–14% van 
alle zwangerschappen voor. De laatste decennia neemt wereldwijd de prevalentie van overgewicht 
en obesitas sterk toe, dit levert mede een belangrijke stijging op van het aantal zwangeren met 
zwangerschapsdiabetes. Onbehandelde zwangerschapsdiabetes leidt tot een verhoogde kans op 
het ontwikkelen van complicaties tijdens de zwangerschap. Complicaties kunnen optreden bij 
zowel moeder als kind en zijn o.a. zwangerschapsvergiftiging, een keizersnede, een kind met een 
hoog geboortegewicht (> 4000 gram), een te laag bloedglucose en geelzucht bij het pasgeboren 
kind. In de jaren na de zwangerschap hebben vrouwen een verhoogd risico op het ontwikkelen 
van diabetes mellitus type 2 en hart en vaatziekten. Tevens hebben de kinderen van moeders met 
zwangerschapsdiabetes een verhoogd risico op het ontwikkelen van obesitas en type 2 diabetes 
mellitus op latere leeftijd. Risicofactoren voor het ontwikkelen van zwangerschapsdiabetes zijn 
o.a: hogere leeftijd van de moeder, niet-westerse afkomst, diabetes mellitus type 2 in de familie, 
zwangerschapsdiabetes in een eerdere zwangerschap, en obesitas. Bij vrouwen met een verhoogd 
risico op zwangerschapsdiabetes wordt meestal gescreend tussen de 24ste en 28ste week van de 
zwangerschap door middel van een 75-g orale glucose tolerantie test. Er is tot op heden geen 
internationale consensus betreft de screening en diagnostiek van zwangerschapsdiabetes. De 
behandeling bestaat uit een dieet en leefstijl adviezen en indien dit onvoldoende effect heeft, wordt 
insuline therapie gestart. Onderzoek heeft aangetoond dat behandeling van zwangerschapsdiabetes 
een vermindering van het aantal ernstige complicaties tijdens de zwangerschap geeft. 
Er zijn nog vele vraagstukken op het gebied van zwangerschapsdiabetes onbeantwoord o.a. met 
betrekking tot de pathofysiologie, effectieve preventie, monitoren van behandeling en lange-
termijn follow-up. Zo is er nog geen adequate test die vroeg in de zwangerschap kan voorspellen 
of een zwangere vrouw diabetes gravidarum gaat ontwikkelen. Onderzoek naar biomarkers die 
detecteerbaar zijn vóórdat er sprake is van verhoogde bloedglucosewaarden, zou de identificatie 
van hoog risico zwangeren kunnen verbeteren. Hierdoor zouden preventieve maatregelen 
toegepast kunnen worden en behandeling in een vroeg stadium toegepast kunnen worden. 
Daarnaast is momenteel ook veel (inter)nationale discussie omtrent de implementatie van de 
“International Association of Diabetes and Pregnancy Study Groups” (IADPSG) diagnostische 
criteria voor zwangerschapsdiabetes. Deze strengere criteria zijn aangenomen door verschillende 
internationale organisaties maar nog niet in Nederland. In het kader daarvan hebben wij onderzoek 
gedaan naar de zwangerschapsuitkomsten van vrouwen die zijn gescreend en behandeld volgens 
de huidige richtlijn “Diabetes en zwangerschap” van de Nederlandse Verneging voor Obstetrie en 
Gynaecologie. 
Er zijn vele successen geboekt op het gebied van behandeling maar veel minder aandacht is er tot 
nog toe geweest voor de lange termijn follow-up na de zwangerschap. Volgens de richtlijn dienen 
vrouwen jaarlijks gescreend te worden op diabetes mellitus type 2 gedurende vijf jaar na de bevallig. 
Of deze aanbevelingen worden opgevolgd in de Nederlandse praktijk was niet bekend. 
Het doel van dit proefschrift was om de klinische uitkomsten en biochemische aspecten van 
zwangerschapsdiabetes te evalueren; van biomarkers & risicostratificatie naar evaluatie van de 
behandeling, en lange-termijn follow-up. 
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In deel I van dit proefschrift bestudeerden wij biomarkers en hun rol in het voorspellen van 
zwangerschapsdiabetes. 
Hoofdstuk 1 geeft een algemene inleiding en beschrijft de doelen van dit proefschrift. 
Hoofdstuk 2 geeft een overzicht van de huidige literatuur met betrekking tot biomarkers bij en 
hun mogelijke rol in het voorspellen van zwangerschapsdiabetes. Laaggradige ontsteking en 
insuline resistentie is verergerd bij zwangerschapsdiabetes. Onderzoek heeft aangetoond dat 
bij vrouwen met zwangerschapsdiabetes er sprake is van een down-regulatie van adiponectine 
en anti-inflammatoire cytokines (adiponectin, interleukine-10) en een up-regulatie van leptine 
en inflammatoire cytokines (interleukine-6, tumor necrosis factor- alpha). Het toevoegen van 
biomarkers aan klinische predictiemodellen zou het identificeren van hoog risico zwangeren kunnen 
verbeteren. Momenteel bestuderen wij de relatie tussen adiponectine en zwangerschapsdiabetes 
en gaan we de voorspellende waarde onderzoeken van adiponectine in combinatie met een klinisch 
predictiemodel. 
 
In hoofdstuk 3 onderzochten we de rol van ghreline als biomarker bij zwangerschapsdiabetes. 
Behoudens het groeihormoonstimulerend effect heeft ghreline ook een belangrijke rol bij de 
glucosehomeostase. Onze hypothese was dat vrouwen met zwangerschapsdiabetes meer insuline-
resistentie en hyperinsulinisme hebben, en daarom lagere ghrelin concentraties dan vrouwen 
zonder zwangerschapsdiabetes. Er werden ghrelin concentraties bij vrouwen met en zonder 
zwangerschapsdiabetes gemeten met behulp van een dubbele anti-lichaam sandwich ELISA kit. 
De resultaten toonde het tegenovergestelde, ghrelin concentraties waren vergelijkbaar in beide 
groepen. Daarnaast werd er een fysiologische daling gezien in ghreline concentraties na inname 
van 75-g glucose oplossing in beide groepen. Dit onderzoek toont aan dat ghreline vooralsnog 
geen geschikte biomarker is in zwangerschapsdiabetes.
In deel II evalueren wij de huidige behandeling van zwangerschapsdiabetes door middel van 
onderzoek naar de zwangerschapsuitkomsten en de wijze van monitoren van de behandeling. 
Tevens onderzoeken wij het effect van metformine bij zwangere vrouwen met een hoog risico op 
zwangerschapsdiabetes. 
In hoofdstuk 4 onderzochten we de zwangerschapsuitkomsten van een grote cohort multi-
etnische vrouwen die gescreend en behandeld waren voor zwangerschapsdiabetes in Rotterdam. 
De zwangerschapsuitkomsten werden vergeleken met zwangerschappen zonder zwanger-
schapsdiabetes (en zonder diabetes mellitus type 1 en 2) verkregen via de stichting Perinatale 
Registratie Nederland. Onafhankelijke voorspellers voor het gebruik van insuline therapie waren: 
BMI ≥ 30, OGTT waarden (nuchter en 2 uur), diabetes gravidarum in de voorgeschiedenis en 
etniciteit (Mediterraan). 
BMI en het gebruik van insuline therapie waren onafhankelijke voorspellers voor het optreden 
van een neonatale complicatie. Het percentage inleidingen van de bevalling was relatief hoog 
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maar dit leidde niet tot extra veel bevallingen met een keizersnede. Wellicht heeft dit er mede 
voor gezorgd dat er een opvallend laag aantal pasgeborenen was dat te zwaar was voor de duur 
van de zwangerschap. Wij concludeerden dat behandeling van zwangerschapsdiabetes volgens 
de huidige richtlijn resulteert in een laag aantal zwangerschapscomplicaties in vergelijking met 
zwangerschappen zonder diabetes.
De behandeling van zwangerschapsdiabetes heeft als doel om normale bloedglucosewaarden 
te bereiken. Inzicht in de glucoseregulatie is daarom essentieel. Momenteel geschied dit via een 
glucose dagcurve door middel van capillaire vingerprikmetingen. In hoofdstuk 5 presenteren wij de 
resultaten van het onderzoek naar het monitoren van de behandeling van zwangerschapsdiabetes. 
We onderzochten de rol van “continuous glucose monitoring” (CGM) voor het aantonen van 
verhoogde bloedglucosewaarden (hyperglycemie) bij vrouwen die behandeld werden voor 
zwangerschapsdiabetes. CGM toonde hyperglycemieën aan, welke niet gedetecteerd waren door 
de standaard glucose dagcurve. De duur van de hyperglycemie was echter niet substantieel. 
In hoofdstuk 6 onderzochten wij het effect van metformine bij zwangere vrouwen met een 
verhoogd risico op zwangerschapsdiabetes. De hypothese was dat het gebruik van metformine 
vroeg in de zwangerschap een effect zou hebben op de incidentie van zwangerschapsdiabetes. 
Het benodigde aantal vrouwen wat nodig was om dit te kunnen onderzoeken werd niet gehaald. 
Desalniettemin, werden er geen nadelige effecten van het gebruik van metformine in de 
zwangerschap geobserveerd. Bewijs dat het gebruik van metformine tijdens de zwangerschap geen 
nadelige lange-termijn effecten bij kinderen heeft is van essentieel belang. 
In het deel III van dit proefschrift werd gekeken naar de lange-termijn follow-up van vrouwen met 
zwangerschapsdiabetes. 
In hoofdstuk 7 presenteren wij de resultaten van een onderzoek naar de screening van diabetes 
mellitus type 2 in de vijf jaar na de bevalling. We toonden aan dat maar ongeveer één derde van de 
vrouwen jaarlijks gescreend werd in de vijf jaar na de zwangerschap. Na het sturen van een reminder 
naar de huisartsen verdubbelde het screeningspercentage bijna. Wij concludeerden dat de huidige 
aanbevelingen voor diabetes screening suboptimaal worden nageleefd. Screening strategieën 
dienen worden te herzien en verbeterd. 
In de discussie gaan we in op de interpretatie van de belangrijkste bevindingen van dit 
proefschrift en de implicaties voor de praktijk (hoofdstuk 8). Tevens geven wij aanbevelingen voor 
vervolgonderzoek. 
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In dit proefschrift laten we zien dat ghreline geen geschikte biomarker bij zwangerschapsdiabetes is. 
De behandeling van vrouwen met zwangerschapsdiabetes volgens de huidige nationale richtlijn is 
succesvol in het verlagen van het aantal complicaties bij moeder en kind. Continue glucosemonitoring 
heeft een beperkte meerwaarde in de detectie van hyperglycemieën vergeleken met een standaard 
glucose dagcurve bij vrouwen die behandeld worden voor zwangerschapsdiabetes. Metformine bij 
zwangere vrouwen met hoog risico op zwangerschapsdiabetes had geen effect op de incidentie 
van zwangerschapsdiabetes maar onderzoek met een groter aantal proefpersonen is noodzakelijk. 
Wel werden er geen ernstige nadelige korte termijn effecten van metformine geobserveerd. Verder 
hebben wij aangetoond dat de huidige aanbevelingen voor lange-termijn diabetes screening niet 
goed worden nageleefd en voor verbetering vatbaar zijn. 
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